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Abstract 
Quantitative Bottom-Up and Top-Down LC/FT-ICR MS for Multisite 
Phosphoproteins and Natural Product Biosynthetic Pathways 
by 
Wendi Anne Hale 
 
Chair: Kristina I. Håkansson 
 Bottom-up (involving proteolysis) and top-down (intact proteins) mass spectrometry 
(MS)-based proteomics are increasingly important tools for protein identification and 
quantitation from complex mixtures.  A multitude of quantitation techniques are available, 
each with advantages and disadvantages, from label to label-free and relative to absolute 
quantitation.  The ultra-high resolution and mass accuracy of Fourier transform ion cyclotron 
resonance (FT-ICR) MS, can improve current quantitation methods.  This thesis presents FT-ICR 
MS-based quantification of proteins and peptides with dynamic post-translational 
modifications, and a novel data-independent liquid chromatography (LC)/FT-ICR MS approach 
for targeted discovery of novel natural product biosynthetic pathways. 
 A novel negative ion mode quantitation method was developed involving standard 
peptides with Val to Leu or Leu to Val substitutions, resulting in similar ionization efficiencies.  
This method was applied to Sic1, a yeast protein with a switch-like response when six out of 
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nine phosphorylation sites are phosphorylated.  With this quantitation technique, the 
phosphorylation kinetics of all nine sites were determined.    
 Relative FT-ICR MS-based quantitation was applied to marine natural product 
biosynthetic enzymes.  Ketosynthase, acyl transferase, and acyl carrier protein (ACP) active site 
occupancies were identified and quantified via LC/FT-ICR MS, as PikAIII, module 5 in the 
pikromycin biosynthetic pathway, completed its catalytic cycle with the addition of  pentaketide 
substrate, methyl-malonyl extender unit, and NADPH.  Several protocol changes were made to 
observe the pentaketide bound to the ketosynthase active site for the first time.  The largely 
homologous jamaicamide (Jam) and curacin (Cur) biosynthetic pathways diverge at an enoyl 
reductase (ER) domain.  Catalytic efficiencies of wildtype and mutant ER domains were 
measured by quantifying ACP-bound product via top-down FT-ICR MS and collision-induced 
dissociation.  Cyclopropanase activity of a novel chimeric ER, designed by inserting a Cur ER 
loop into Jam ER was measured via FT-ICR MS.   
 Finally, a novel data-independent acquisition method was developed for targeted 
discovery of novel natural product biosynthetic pathways from unsequenced organisms.  This 
technique utilizes the resonant IR absorptivity of a secondary phosphate in the ACP 
phosphopantetheine modification.  Peptides with this modification dissociate with high 
efficiency upon IR irradiation, whereas unmodified peptides are largely unaffected by IR 
irradiation. 
 
 
1 
 
 
Chapter 1 
 
Introduction 
 
1.1 Mass Spectrometry for Proteomics 
 
 The field of proteomics, the study of the proteome, has exploded in the last few 
decades.  The proteome encompasses all proteins expressed in complex tissues, cells, or whole 
organisms1.  Proteomics aims to investigate the function of all proteins, including their 
structure, interactions with other proteins, and composition3,4.  Proteomics is affected by many 
challenges due to differences in expression level, hundreds of post-translational modifications 
(PTMs), dynamics in interactions, and sample preparation for analysis3,4.  Many biochemical and 
biophysical techniques are available to study proteins, including surface plasmon resonance, 
circular dichroism, fluorescence, and Raman spectroscopy, mass spectrometry (MS), nuclear 
magnetic resonance spectroscopy, X-ray crystallography, and electron microscopy5,6.  While 
each technique has its own set of advantages and disadvantages, mass spectrometry is an ideal 
tool for proteomics7: MS offers high  sensitivity for complex and low abundance proteins, 
including flow rates at picoliters per minute, consuming only zeptomoles of peptide8 while also 
being able to detect, quantify, and localize PTMs9.  In addition to high sensitivity, high mass 
accuracy and high-throughput are other requirements of proteomics, both achieved by mass 
spectrometers10,11.  Mass accuracy can easily reach less than 5 ppm on high performance mass 
spectrometers such as Orbitraps and Fourier transform ion cyclotron resonance (FT-ICR) mass 
spectrometers12-14. 
 There are three complementary approaches to performing proteomics by mass 
spectrometry: bottom-up, top-down, and the more recent middle-down approach.  
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Figure 1.1. Schematic of top-down, middle-down, and bottom-up mass spectrometry for 
deducing protein primary sequence information.  Reprinted with permission from Switzar et al. 
Copyright 2013 American Chemical Society15. 
 
Bottom-up mass spectrometry is arguably the most widely utilized approach in 
proteomics and is ideal for protein identification while also providing localization of PTMs16.  
One or more proteins are subjected to proteolysis by one or more proteases15,17.  The resulting 
peptides are usually separated by reverse phase high performance liquid chromatography 
(HPLC) and then are analyzed by mass spectrometry18-21.  Multidimensional protein 
identification technology (MudPIT) directly combines strong cation exchange with reverse 
phase HPLC22.  Samples can also be pre-fractionated followed by HPLC/MS analysis of the 
resulting fractions.  Peptides typically undergo fragmentation via tandem mass spectrometry 
(MS/MS) and the resulting fragment masses are compared to a genome-derived database using 
algorithms such as MASCOT or Sequest7,16,23,24.  Although collision induced dissociation (CID)25,26 
is the most common MS/MS activation technique, other methods are becoming increasingly 
popular, especially for their ability to retain PTMs.  Examples of alternative MS/MS techniques 
include infrared multiphoton dissociation (IRMPD)27, electron capture dissociation (ECD)28, 
electron transfer dissociation (ETD)29, negative electron transfer dissociation (nETD)30, negative 
ion electron capture dissociation (niECD)31, electron detachment dissociation (EDD)32, electron 
induced dissociation (EID)33-35, and ultraviolet photo dissociation (UVPD)36,37.  In bottom-up 
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proteomics, no prior knowledge of a protein’s sequence is required for identification as long as 
it is present in the utilized database23.  In addition, the fragmentation pathways/bond cleavage 
preferences of the utilized MS/MS technique must be known.  Although bottom-up mass 
spectrometry is a sensitive technique that works well for protein identification, it is challenging 
to achieve 100% sequence coverage, due to ion suppression, sample loss during separation, or 
when the same or similar peptide sequence occurs multiple times in a single protein or occurs 
in multiple different proteins19.   
 Top-down proteomics measures the intact mass of one or more proteins and 
subsequently dissociates the protein or proteins inside the vacuum of the mass 
spectrometer19,38.  Top-down analysis is best applied to protein identification and structural 
characterization, including identification and localization of PTMs39.  Combinatorial PTMs, 
where multiple PTMs affect protein function, e.g., binary switches in histones and 
phosphorylation, can be more fully understood and characterized if they are located on the 
same polypeptide chain40.  Top-down MS analysis is emerging as a technique in structural 
biology41.  Protein-protein, protein-peptide, and protein-ligand binding sites and interactions 
can be determined with, e.g., ECD, as it can cleave the backbone of the protein or peptide 
without disrupting non-covalent interactions42-45.  The advantages of top-down proteomics are 
numerous and counteract the disadvantages of bottom-up proteomics.  For example, bottom-
up proteomics rarely provides 100% sequence coverage, while this is possible and fairly 
common in top-down proteomics19.  As aforementioned, ECD and ETD provide complementary 
sequence information to CID and they are more efficient with increasing charge, which is 
readily available on intact proteins.  Top-down analysis sample preparation time is shortened 
without proteolysis41 although it also comes with its own challenges and shortcomings.  Intact 
proteins have a higher detection limit and have lower sensitivity than peptides due to lower 
ionization efficiency and dilution of signal over many charge states upon electrospray ionization 
(ESI), thus proteins must have a high purity for top-down MS to work well38.  Fragmenting an 
intact protein results in complex MS/MS spectra and thus high resolution is typically required.  
It has been historically challenging to detect intact proteins without a time-of-flight mass 
analyzer, which may lack the resolution required to resolve the protein and high mass 
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fragments38.  However, recent advancements have allowed large proteins, above 100 kDa to be 
detected by other mass spectrometers, including Orbitraps and FT-ICRs46-48.    
Middle-down mass spectrometry is an emerging technique that combines the 
advantages of bottom-up and top-down mass spectrometry15.  Middle-down MS analyzes large 
peptides that range in size from 2 to 20 kDa, whereas bottom-up peptides are typically less 
than 3 kDa15.  These large peptides can be produced by incomplete digestion with traditional 
bottom-up proteases such as Glu-C, or proteases that cleave in few specific areas, such as outer 
membrane protease T (OmpT) or immunoglobulin G-degrading enzyme from S. pyogenes 
(IdeS)49-51.  Although the concept of middle-down MS for proteomics is somewhat new, 
pharmaceutical companies have been performing middle-down analysis in a targeted manner 
by digesting antibodies with endoproteinase Lys-C to create large peptides for disulfide 
mapping for years52,53.  Middle-down MS is also beneficial for untargeted proteomics, as it is 
able to distinguish between protein isoforms and can detect and identify peptides with 
modifications, particularly combinatorial PTMs, traditional benefits of top-down MS50,54,55 while 
avoiding the ionization efficiency issue associated with top down analysis.  Middle-down 
proteomics has advanced recently, for example by the introduction of OmpT, a protease 
developed by the Kelleher group to create peptides greater than 2 kDa.  Larger peptides can be 
advantageous in proteomics experiments because electron based methods, such as ECD and 
ETD, are complementary to CID and are more efficient when the peptide has more charges50,55.  
Larger peptides are able to provide information on combinatorial PTMs, e.g., in histones that 
have a high number of isoforms with high sequence homology, traditionally an advantage of 
top-down proteomics50,55,56.  As the middle-down MS approach is combining the positive 
attributes of bottom-up and top-down protein MS, it appears that there are few disadvantages 
to middle-down analysis.  However, it is still an emerging technique.    
 
1.2 Protein MS Quantitation Methods 
 
 Protein PTMs are highly dynamic and thus change abundance readily, particularly if they 
are involved in cell regulation.  Quantitation is important for determining both the amount of a 
specific protein in a system and the fold change in response to either diseases or drugs24,57.  
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Mass spectrometry-based quantitation is more universal than other biochemical quantitation 
methods, such as immunoassays, as they may incur non-specific protein binding, and can detect 
small changes to the protein such as modifications58.  There are multiple ways to categorize 
MS-based quantitation methods.  The main category is label versus label-free quantitation and, 
within those two groups, there is global versus targeted and relative versus absolute 
quantitation. 
 
1.2.1 Protein quantitation involving labeling methods 
 
 One of the most popular labeling methods is stable isotope labeling by amino acids in 
cell culture (SILAC).  Since its inception in 2002, over five hundred papers employing or 
reviewing SILAC have been published59.  Although it is a relative quantitation method, it is 
arguably the most accurate technique and can be applied to global proteomics.  Amino acids 
are added into two sets of cell culture; one set has no label, while the other set of amino acids 
is labeled with heavy stable isotopes60.  Leucine labels are common, as they are the most 
common amino acid and label about seventy percent of tryptic peptides, or lysine and arginine, 
which guarantee at least one label per tryptic peptide24.  After performing protein expression, 
the labeled and unlabeled proteins from the two cell cultures are mixed in a 1:1 ratio, digested 
and analyzed by MS60.  Labeled and unlabeled peptides elute at the same time during 
chromatography but differ by a certain mass, depending on the label57.  Although SILAC 
requires living cells and can be quite costly, it functions well in mammalian, yeast, and bacterial 
cell cultures and has low variance because the labels are introduced at the organism level in 
model organisms57,60,61.  The versatility of SILAC allows for many applications, including protein 
turnover, monitoring PTM dynamics such as phosphorylation and histone modifications62-66.  
SILAC’s flexibility allows for variations, such as neutron encoding (NeuCode) SILAC.  This 
technique requires ultra-high resolution as it exploits the millidalton differences in different 
combinations of SILAC isotopologues67.  NeuCode increases the dynamic range of traditional 
SILAC without complicating the mass spectrum, as the mass differences are too small to 
observe with low resolution67.  Comparable to SILAC, 15N metabolic labeling for plant 
proteomics works by growing half of the plant cells in medium enriched with over ninety six 
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percent 15N NH4Cl68.  An alternative method is feeding the plant with an inorganic nitrogen 
source enriched in 15N, leading to 15N incorporation into the amino acids and therefore 
proteins.  The advantages of this approach are also comparable to SILAC:  it is an accurate 
technique, applicable to global proteomics, can determine changes in protein expression, and 
can detect changes in PTM amounts57,68.  Like SILAC, 15N labeling can be applied to protein 
turnover calculations, and can interrogate plant metabolism and quantitatively compare multi-
protein plant complexes in different strains69-71.  There are some limitations to this technique; 
due to the large number of nitrogen atoms in any peptide sequence, it is possible to partially 
label nitrogens, which can lead to ambiguous data interpretation24.  Further, the number of 
nitrogen atoms is dependent on the peptide sequence length, so each labeled peptide has a 
varying mass difference24.   
 Chemical, or in vitro, labeling is another common technique for protein and peptide 
quantitation.  Isotope-coded affinity tags (ICATs) have specific reactivity with thiol groups and 
thus covalently attach to cysteine sidechains.  A linker group incorporates stable isotopes for 
light or heavy labeling with hydrogens or deuteriums, and a biotin tag is included for affinity 
purification72.  Two sets of protein samples are labeled with ICAT (light vs. heavy), digested, 
enter an avidin column, and are then subjected to LC/MS analysis24.  The resulting light and 
heavy pairs of peptides have a fixed 8 Da difference, making data analysis simpler than 
metabolic labeling72.  Despite the improvements in simplicity, ICAT is only applicable to 
peptides with cysteine residues, only including about twenty percent of peptides57.  The ICAT 
tags are fairly large, which influence MS/MS fragmentation patterns and the deuterium labeling 
affects coelution of the paired peptides24.  The latter issue has been solved by creating a 
cleavable tag that allows coelution73,74.  Peptide dimethyl labeling is achieved by a reductive 
amination reaction with formaldehyde and deuterated formaldehyde, respectively, resulting in 
the dimethyl label on the N-terminus and lysine sidechains of the peptides75.  The mass 
difference between labeled and unlabeled peptides is 28 Da, the labeling reaction is 
inexpensive and takes less than five minutes75.  The hydrogen and deuterium labeled peptides 
have similar retention times, however they are different enough such that data analysis is 
complicated, as peptides are not in the same spectrum, rendering relative quantitation more 
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difficult75,76.  Absolute quantification using synthetic standard peptides (AQUA) is one of the 
few absolute quantitation strategies.  Synthesized isotopically labeled peptide standards at a 
known concentration with identical sequences to the peptides in question function as internal 
standards77.  Although this approach has been in use for non-proteomic applications for a few 
decades prior to the introduction of AQUA, the technique did not become popular until many 
other peptide quantitation techniques were developed78.  The concentration of the peptide of 
interest can be calculated based on the internal standard peptide.  Because the peptides are 
chemically identical, they will have the same retention time77.  To reduce signal interference 
from other peptides, selected or multiple reaction monitoring can be performed on the peptide 
fragments for quantitation24.  This universal technique can be applied to any peptide, because 
the isotopic label can be added to any amino acid.  AQUA has the potential to give insight into 
dynamic changes in protein and peptide levels, even if they are modified and of low 
abundance77.  Although this technique is robust and very specific, sample preparation may 
affect the true concentration of the peptide in question57,76. 
Isobaric tags for relative and absolute quantitation (iTRAQ) is another labeling technique 
that adds isobaric mass labels at the N terminus and lysine side chains of peptides79.  The labels 
do not increase spectral complexity, as each labeled peptide is isobaric, however upon MS/MS, 
reporter ions of different mass are among the product ions and are the peaks used for 
identification and quantitation79.  The reporter ions range between 114.1-117.1 Da and the 
mass balance group ranges between 28 and 31, so that the mass spectra all contain the same 
added mass, 145.1 Da79.  The main advantage of this technique is that quantitation for more 
than two peptides is possible; originally iTRAQ was designed for multiplexing with 4 peptides 
and is now capable of 8-plexing79-81.  iTRAQ is applicable for absolute quantitation which can be 
obtained by adding an iTRAQ tag to a synthetic standard peptide79.  Although iTRAQ is an 
overall robust technique, it suffers from isotopic interference and low signal-to-noise, affecting 
quantitation82.  However, when a fragment ion is further isolated and fragmented in an MS3 
experiment, isotopic interference is greatly reduced due to the secondary isolation83.  Tandem 
mass tags (TMTs) are similar to iTRAQ in that they are also isobaric tags that are revealed upon 
MS/MS84.  The tags consist of two or three parts: an amino acid tag group linked to a guanidino 
8 
 
functionality for sensitization and a mass normalization amino acid, while a second generation 
of tags includes a proline for cleavage enhancement84.  The tag attaches to the N-terminus or a 
lysine sidechain of the peptide.  Like iTRAQ, tagged peptides co-elute, which simplifies 
quantitation, allowing for comparison of relative ion abundances in a single spectrum.  Overall, 
both isobaric labeling techniques are less accurate than SILAC, because their accuracy depends 
on the isolation width of the precursor ions for fragmentation, where all isolated ions will 
contribute to fragments in the reporter ion mass ranges57.  iTRAQ is now a trademark by AB 
Sciex and is sold by AB Sciex and Sigma Aldrich, while TMTs are sold by Thermo Scientific.   
 
1.2.2 Label-free quantitation 
 
Label-free quantitation techniques are emerging as increasingly popular and simpler 
quantitation approaches, as they do not involve extra chemical reactions, are generally less 
expensive, have high proteome coverage and can be applied to a large variety of biological 
samples85.  There are three main label-free strategies; one measures the abundance of 
precursor ion peaks, one measures the number of fragment ion peaks, while the last one makes 
use of indices76. 
Spectral counting is a relative quantitation technique that works by counting the 
number of MS/MS peaks from a protein, which directly corresponds with protein 
abundance61,86.  Proteins are identified via a database based on the MS/MS spectra; next, all of 
the MS/MS peaks from a single protein are added together based on their peak area, then this 
peak area is normalized to the peak area of an internal standard protein digest at a specified 
concentration87.  An advantage of spectral counting is that the MS/MS data not only provide 
quantitative information, but also provide a plethora of identification information76.  Spectral 
counting is very accurate for measuring large changes in protein abundance but is less accurate 
with smaller changes61.  Another disadvantage is that dynamic exclusion during online 
LC/MS/MS can affect the quantitative accuracy rate, as the basis of spectral counting is that the 
abundance of a protein correlates with the amount of times a corresponding peptide is isolated 
and fragmented 76.  Further, LC/MS/MS runs are repeated multiple times for quantitation and 
there is a possibility that the same peptides are selected in each run, thus biasing the data24. 
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Generally, signal abundance from electrospray ionization directly correlates with the 
concentration of the ion88.  Extracted ion chromatogram (XIC)-based quantitation involves 
creation of extracted ion chromatograms for the same peptide across different LC/MS runs24.  
For this technique to successfully relatively quantify a peptide in question, the sample handling 
must be the same between both runs to reproduce spectral total ion abundance, background 
peptides and contaminants, thus ensuring similar peptide ionization efficiency24,57.  
Quantitative accuracy depends on signal to noise ratio: if the peptide abundance is near the 
noise, the accuracy will decrease24.  There is always some variability between two LC/MS runs, 
even if they are performed under identical conditions, therefore some sort of normalization is 
necessary, such as a background peptide that will not change abundance24,86.  This technique in 
particular has been applied to determine phosphorylation stoichiometry89.  XIC-based 
quantitation works best with high mass accuracy mass spectrometers, so that peptides with 
similar, but not identical, masses are not chosen for quantitation76.  Overall, XIC-based methods 
can suffer from variability due to non-identical conditions between LC/MS runs.  In addition, 
HPLC retention times must be highly reproducible.   
Absolute quantitation with label-free techniques makes use of derived indices, such as 
protein abundance indices, and therefore do not require internal standards.  The exponentially 
modified protein abundance index (emPAI) is an index that shows a logarithmic relationship 
between the number of peptides observed and the protein amount in a certain sample90.  
emPAI was first demonstrated with 46 proteins in a whole cell lysate from a mouse90.  An 
emPAI is calculated by the number of observed spectra for each protein divided by the number 
of observable peptides57.  The index is normalized and takes into account that larger proteins 
will create more peptides than a smaller protein90.  emPAI is easily calculated from values 
provided by databases such as Mascot and does not need additional experimentation86,90; 
however, emPAI is less accurate with low resolution mass spectrometers and may become 
saturated with highly abundant proteins, thus decreasing the sensitivity of the technique90.  
Additionally, emPAI will not produce accurate results if peptides overlap, which will occur more 
often with larger proteins, presenting a size limitation to this technique91.  Absolute protein 
expression measurements (APEX) is another index-type quantitation method that measures the 
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absolute protein concentration per cell based on the proportion between the protein 
abundance and the number of peptides observed86,92.  There are a number of correction factors 
in APEX that create the proportionality between the observed and expected number of 
peptides found86.  The APEX score provides the protein abundance based on the fraction of 
observed peptide mass spectra associated with a protein, and is corrected by an estimate of the 
number of unique peptides expected, calculated from online databases86.  APEX is able to 
determine the absolute protein expression within a correct order of magnitude and correlates 
well with other measurements such as 2D gel electrophoresis76,92.  Issues and biases in bottom-
up proteomics such as ionization and solubilization are already corrected for in APEX92.  APEX 
may be applied to biomarker discovery or serum profiling, and can also estimate protein 
degradation rates92.  The derived indices also suffer from caveats; because they calculate scores 
from online databases, these methods are limited to positive ion mode.   
 
1.3 Liquid Chromatography and Mass Spectrometry Instrumentation 
 
1.3.1 Liquid chromatography 
 
 High performance liquid chromatography is an analytical chemistry technique that 
separates a wide variety of components.  When coupled to a mass spectrometer, it is often 
used for separation of complex mixtures or desalting and cleanup prior to analysis. The first 
example of chromatography was shown by Mikhail Tswett in 1903, while the first HPLC was 
designed by Csaba Horvath in 1965 to separate nanomolar mixtures of small organic molecules, 
however, the application of LC has greatly expanded and is now essential to the proteomics 
field93. 
 The LC consists of multiple parts, starting with the solvents flowing through a degasser.  
Each solvent is pushed through its own pump and solvents are then mixed together.  The mixed 
solvents flow through a cooled autosampler, where the sample of interest is stored and 
injected onto an LC column.  The LC column consists of a stationary phase and a mobile phase, 
typically encased in stainless steel for high flow columns (~mL/min).  The most common 
stationary phase consists of silica particles, although alumina is another potential material94.  
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The bonded stationary phase is covalently attached to the silica and interacts with the 
analytes94.  For reverse phase chromatography, the bonded stationary phase is non-polar and 
either has an octadecyl (C18), octyl (C8), or phenyl (C4) group, while the mobile phase solvent is 
more polar94.  Analytes are detected as they are eluted from the column.  Although, there are a 
number of detection methods, the HPLC in the Hakansson lab has a UV detector, normally set 
to 214 nm, where the peptide amide bond absorbs.  UV detectors are among the most common 
detectors in LC because many analytes absorb ultraviolet light94.  After UV detection, the 
analytes are further analyzed in the mass spectrometer.  Several factors can contribute to 
separation and its resolution.  Solvent choices and the shape of the LC gradient are two of these 
factors.  In reverse-phase chromatography, solvent A is generally water, while solvent B is 
usually acetonitrile or methanol.  Solvents typically have about 0.1% of an organic acid, such as 
formic acid, which aids with positive ion mode ionization, which will be discussed in the next 
section.  A gradient, starting at low organic solvent and increasing to high organic solvent can 
greatly aid in separation of analytes.  A shallower gradient can separate peaks well, although 
this action will increase the time, another factor that should be considered.  A lower flow rate, a 
longer column, and a smaller particle size generally improves resolution94.  A column’s 
efficiency is measured by its number of theoretical plates, N= L/H, in which L is the length of the 
column packing and H is the plate height.  The van Deemter equation illustrates the efficiency 
of a column as function of flow rate: 
 
 (1)  H = A + B/u + CSu + CMu 
 
in which H is the plate height, the A term is Eddy diffusion, the B term is the longitudinal 
diffusion coefficient, and the C terms are the mass-transfer coefficients of the stationary and 
mobile phases, respectively95.  Eddy diffusion is affected by the multiple ways an analyte can 
travel through a packed column; because the same type of molecule will travel through the 
column by different paths, the molecules will arrive at the detector at different times, which 
causes zone broadening, also referred to as the Random Walk Model95,96.  The B term is 
affected by the tendency of a solute to migrate from a concentrated to a dilute section of a 
band, both with and against the flow of the solvent95.  The C terms consider the time that the 
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analytes take to be adsorbed and desorbed into/off from a porous particle, as well as stagnant 
mobile phase stuck in the particle95. 
Advancements in separations have led to smaller columns and smaller stationary 
particles, resulting in an increased pressure.  To accommodate for these innovations, ultra high 
performance liquid chromatography (UHPLC) and nanoflow-LC have been developed.  UHPLC 
utilizes packing material particles less than 2 µm and LC pressures up to 1200 Bar to achieve 
increased separation efficiency and shorter analysis time97-99.  Smaller sized particles reduce the 
mobile phase C term from the van Deemter equation, which in turn reduces the plate height97.  
Karlsson and Novotny first discovered that a smaller inner diameter correlates with a lower 
plate height for slurry-packed capillary columns,100 the first nano-LC, although this 
improvement was first predicted by Jorgenson101.  Due to a decreased flow rate, less sample 
and solvent is consumed and the sensitivity is increased102,103.  UHPLC systems and nano-LC 
systems are commercially available and popular in both industry and academic laboratories. 
 
1.3.2 FT-ICR mass spectrometry 
 
Fourier transform ion cyclotron resonance mass spectrometry is one of the most 
powerful mass analysis methods that exists today, due to its ultra high resolution, unmatched 
mass accuracy, and its ability to execute many MS/MS fragmentation techniques.  The following 
description of FT-ICR MS specifically applies to the Apex and SolariX models manufactured by 
Bruker Daltonics.  However, the general principles of each part may apply to more than one 
model or instrument.  
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Figure 1.2. Schematic diagrams of Apex (top) and SolariX (bottom) FT-ICR mass spectrometers.  
 
 Molecules of interest enter the mass spectrometer via an ionization and volatilization 
technique.  One of the most common ionization techniques for large biomolecules is 
electrospray ionization.  To facilitate ESI, the sample should be dissolved in water, an organic 
solvent, and either a small percentage of acid or base, although this solvent combination may 
disrupt the native structure of the analyte.  The organic solvent improves solvent volatility, 
aiding in solvent evaporation, and decreases the surface tension of the sample while the acid or 
base promotes protonation or deprotonation of the analyte, respectively.  The two classic 
mechanisms for ESI are the charge residue mechanism104,105 and the ion evaporation 
mechanism106.  In ESI, the aqueous sample is infused through a capillary needle into the source 
region which, in our instruments, is biased at ~4000 volts for negative ion mode and ~-4000 
PL1 
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volts for positive ion mode at atmospheric pressure.  Typically, the capillary needle is connected 
to high voltage; however, on our instruments, the spray needles are grounded for safety 
purposes and the end of a glass capillary, constituting the entrance to the mass spectrometer, is 
supplied with high voltage instead.  The glass capillary is a hollow, glass tube with an inner 
diameter of about 0.75 mm, coated with platinum on both ends, to provide separate 
conductivity at the two ends.  Due to the high electric field between the ESI capillary needle and 
the glass capillary inlet to the mass spectrometer, there is a buildup of charge at the surface of 
the ESI capillary needle that faces the electric field.  The charge buildup causes destabilization 
of the meniscus and draws it out into a Taylor cone.  Nitrogen nebulizing gas aids in breaking 
the meniscus of the surface, and also helps the Taylor cone form.  The liquid Taylor cone exists 
due to the competition between the high electric field and the surface tension of the charged 
liquid104.  Charged droplets are formed at the tip of the Taylor cone and are expelled from the 
cone due to charge repulsion.  The charged droplets shrink in size as they evaporate with the 
aid of heated nitrogen drying gas.  As the droplet size shrinks, the charge density in the droplets 
increases and the droplets undergo Coulomb fission as they reach the Rayleigh limit, defined in 
Equation 2: 
 
(2)  qR = 8π𝜀0
1/2
 σ1/2 r3/2                  
 
in which qR is the droplet charge, r is the droplet radius, ε0 is the vacuum permittivity, and σ is 
the surface tension of the droplet.  When the Rayleigh limit occurs, the droplets explode and 
form smaller ‘progeny’ droplets107.  In the charged residue mechanism this process continues 
and the droplets become increasingly smaller, down to a few nanometers in radius108.  Once 
the droplets have reached this size, they are completely desolvated and analytes are in the gas 
phase.   
In the ion evaporation mechanism, the charged droplets are formed in the same manner 
as the charge residue mechanism.  However, the transformation of analytes from droplets into 
the gas phase is quite different.  In the ion evaporation mechanism, the droplets undergo 
fission to a lesser extent, thus involving larger droplets. The buildup of charge in the droplets 
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causes the surface electric field to increase until it directly desorbs analyte ions from the 
surface of the droplets107.  Both of these mechanisms can account for several theories on ion 
suppression.  Many investigators agree that substances such as salts or other biological entities 
mixed with the analyte of interest increase the surface tension of the droplets formed from the 
Taylor cone, preventing droplets from shrinking and evaporating at the same rate and thus 
decreasing the overall formation efficiency of gas phase ions109-112.  Another theory states that 
charged substances compete with the analyte of interest for space at the surface of the 
droplet112.  Ion suppression occurs as contaminants and other charged substances enter the gas 
phase along with the analytes of interest and dominate the signal from the mass spectrometer.   
After the ions exit the glass capillary, they enter the first ion funnel.  There is a 
deflection plate that is at a ninety degree angle to the capillary and faces the ion funnels, thus 
directing ions away from the plate and toward the funnels.  The main purpose of the ion 
funnels is to increase sensitivity by compressing ions together to form a more focused ion 
beam.  The ion funnel is made of ring electrodes that decrease in diameter further into the 
instrument113.  There is a DC potential gradient along the ring electrodes thus forming an 
electric field which pushes the ions into the instrument.  An added RF field focuses the ions 
radially toward the center of the funnel113, so that the ion beam fits through the end of the 
funnel, corresponding to Skimmer 1.  The purpose of the skimmers is to maintain the pressure 
difference between the source region and the lower pressure regions closer to the ICR cell114.  
The difference in the skimmer voltages affects ion transmission efficiency114.  There is an 
additional ion funnel and skimmer following Skimmer 1.  However, the second ion funnel is 
significantly shorter in length than the first ion funnel in the SolariX instrument and slightly 
shorter in the Apex instrument.   In general, the voltages from the source through the second 
skimmer decrease to allow the ions to gently make their way through the mass spectrometer.  
After the ion funnels come a series of multipoles: a hexapole, a quadrupole and a 
second hexapole in the Apex instrument.  The first hexapole continues the work of the ion 
funnels, keeping the ions together in a packet115, so they are transmitted efficiently into the 
infinity ICR cell.  The first hexapole is vital in converting the continuous ion beam into an ion 
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packet.  In the SolariX instrument, a split octopole replaces the first hexapole.  The following 
quadrupole can be utilized for mass selection and the second hexapole acts as the collision cell.   
 Another important point regarding the multipoles is the pressure change compared to 
the source.  The collision cell, which is the third multipole, has a local higher pressure, closer to 
1x10-3 mbar to ensure efficient ion cooling in this area, although the gauge reads a lower 
pressure because of its placement on the instrument. The pressure then continues to decrease 
closer to the ICR cell.  The increased pressure in the third multipole is achieved by adding argon 
to this area.   
A greater number of poles decreases the oscillating radius of ions travelling through a 
multipole, therefore a hexapole is more efficient for ion transmission than a quadrupole115.    In 
both of our mass spectrometers, hexapoles or octopoles are utilized for ion transmission, while 
the quadrupole is utilized for both ion transmission and isolation, which will be described later.  
This advantage is shown in Equation 3115: 
(3)    𝑅𝑘,𝑖 =  𝜌 [
∑ 𝑄𝑗
𝑖+𝑘−1
𝑗=1
𝑞𝑁𝑖𝑄𝑚𝑎𝑥
] ^
1
2(𝑁−1)
 ; k = 0,1; 𝑖 = 1, … , 𝑁𝑠𝑝𝑒𝑐 ; 𝑞𝑁𝑖 = 2𝑁 (𝑁 − 1)
𝑒𝑧𝑖𝑉𝑅𝐹
𝑚𝑖𝜔
2𝜌2
 
 
 in which N is the number of poles, R is the radial range, Q is the linear (axial) charge density, k 
is the inner and outer radius of the ion cloud, ρ is the inscribed radius of the multipole, VRF is 
the radiofrequency (RF) amplitude, and ω is its angular frequency, qn is the space charge 
density, m is the ion mass, e is the elementary charge, and Qmax is the axial space charge limit 
for a multipole.  i represents each ion species, while k represents an index, designating the 
inner and outer radius, in which k= 0 and k= 1, respectively.  If the radius of the ion cloud is too 
large, the ions may collide with the poles and lose their charge.  RF-only quadrupoles are more 
likely to ‘overfill’ and reach storage capacity than other multipoles, because RF confinement in 
a quadrupole is less efficient for more energetic ions compared with higher order multipoles.  
This action tends to discriminate against higher m/z species.  A greater number of poles reduces 
the radius of the ion packet, therefore combatting the effects of space charge.   
The middle multipole, the quadrupole, consists of 4 poles with the same RF potential 
except that adjacent poles are 180° out of phase with each other and thus have opposing 
polarities.  The poles across from each other have the same DC and RF potentials, including the 
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same polarity and magnitude.  If an RF only potential is applied, the quadrupole will not act as a 
mass filter and all ions will pass through except for ions that fall below the low mass cutoff.  
Ions of very low mass are not stable, because they do not fall within the limits of the ion 
stability diagram.  These ions will have an unstable trajectory, quickly increasing their oscillation 
amplitude and thus eventually hitting a pole or exiting the electric field116.  When there is 
superimposed DC potential, the Mathieu equation can be applied to demonstrate a quadrupole 
acting as a mass filter: 
(4)   
𝑑2𝑢
𝑑𝜉2
+ (𝑎𝑢 − 2𝑞𝑢 cos 2𝜉)𝑢 = 0 , 
 
in which u is the x- or y-coordinates, a and q are trapping parameters (see below) , and ξ is 
equal to Ωt/2, in which Ω is the RF frequency117.  The Mathieu equation may be rearranged and 
reduced to the Mathieu parameters, shown below, in which a and q act as parameters for the 
mass filter118.   
(5)  qu= 
4eV
m𝑟0
2𝛺2
     𝑎𝑢 =
8𝑒𝑈
𝑚𝑟0
2𝛺2
 
In these parameters, e is the elementary charge, m is the mass, r0 is the inscribed radius of the 
quadrupole (8.3 mm in our FT-ICR), Ω is the RF frequency (880 kHz), U is the DC voltage, and V 
represents the RF amplitude.  When these two parameters are plotted against each other, an 
ion stability diagram is created.  The electric field is hyperbolic in shape and ions lying within 
the a and q region are filtered through, while ions outside of this range collide with a rod in the 
quadrupole, or escape between the rods and do not make it through.  An ideal quadrupole 
forms a symmetric hyperbolic shape, whereas an ideal hexapole’s electric field is more complex 
and non-hyperbolic in shape.  The quadrupole’s symmetrical electric field is ideal for a mass 
filter.  The quadrupoles on our mass spectrometers are equipped with a pre- and post-filter 
which are shorter quadrupoles that sandwich the main quadrupole118.   Both filters are RF-only 
quadrupoles and their purpose is to transition the ions in and out of the quadrupole because of 
the potentially disruptive DC potentials118.  The filters act as buffers between each multipole 
and simulate an infinitely long quadrupole. 
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The hexapole following the quadrupole serves as both the collision cell and an ion trap 
to store and accumulate ions before they enter the ICR cell.  The entrance and exit lenses are 
placed at either end of this hexapole so that they can act as an axial trap.  The ion accumulation 
time is a tunable parameter, which stores the ions in the hexapole for a given amount of time.  
The ions exit the hexapole by pulsing the entrance and exit lenses, as well as the DC offset on 
the hexapole.  When this hexapole acts as the collision cell, the MS/MS technique CID occurs.  
Quadrupole-selected precursor ions undergo higher energy collisions with the added argon gas 
as a result of increasing the potential difference between the first and third multipole.  The 
kinetic energy from these collisions is converted to precursor ion internal energy25.  This 
imparted energy vibrationally excites the precursor ion and the energy is distributed over all of 
the bonds in the ion.  The most labile bonds are subsequently cleaved and the precursor ion is 
depleted into fragments.  For example, in a peptide, the higher vibrational energy results in 
migration of mobile protons to backbone amide nitrogens, weakening  and cleaving peptide 
backbone bonds to yield N-terminal b- and C-terminal y-type ions119.  Neutral losses, such as 
water and ammonia are also common in CID of peptides. 
 The ion transfer optics following the collision cell are an additional important feature 
and, in the Apex instrument, are comprised of a series of lenses that transport the ions through 
the magnetic field gradient.  Because the superconducting magnet surrounding the ICR cell is 
actively shielded for safety purposes this gradient is steep.  The ion optics accelerate the ions 
axially so that they are efficiently transferred to the ICR cell for analysis.  The first lens, PL1 
(Figs. 1.2 and 1.3), has a high DC voltage that keeps the ions in the center of the lens.  It also 
contributes to the axial acceleration120.  The second and third lens, PL2 and PL4 (Fig. 1.3), 
perform vertical and horizontal ion packet deflection, respectively, and help direct the ions 
towards the ICR cell.  DPL2 and DPL4 (Fig. 1.3) are differential parameters between these 
lenses.  Their purpose is for low energy beam steering and these parameters are quite 
sensitive120.  These two parameters are generally kept at or very close to 0 V so that the ions 
remain on axis.  The next lens is the HVO (Fig. 1.3), which is kept at high voltage, generally -
2900 V for positive ion mode.  The HVO voltage is distributed over the entire set of transfer 
optics lenses to create a potential well (Fig. 1.3).  There are deflection plates in the lens that 
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steer the ion beam in both the x-and y-directions120.  The voltages on the deflection plates are 
fairly low, generally between 50 and 70 V.  The FOCL1 and FOCL2 lenses (Fig. 1.3) as well as the 
PL9 lens (Fig. 1.3) focus the ions further.  The latter lenses also slightly decelerate the ions, so 
that the voltage differential between the HVO and the low voltage ICR cell trapping potentials is 
minimized.  The PL9 lens is an Einzel lens which helps focus the ion beam without changing its 
energy120.  The SolariX instrument has a single transfer hexapole in lieu of the high voltage ion 
transfer optics, accounting for an order of magnitude increase in sensitivity for SolariX.   
 
Figure 1.3.  Diagram of the ion transfer optics lenses and the electric potential well in the Apex 
FT-ICR mass spectrometer120. 
  
In FT-ICR MS, the ICR cell is the mass analyzer and detector.  The cell is kept at ultrahigh 
vacuum, with the pressure in the 10-10 mbar range.  The cell is held in the bore of the 
superconducting magnet; both of our magnets have a field strength of 7 Tesla.  Although the 
bore of the magnet is at room temperature, the coil is kept at 4 K to keep the magnet 
superconducting.  On the Apex instrument, a liquid nitrogen region surrounds a liquid helium 
region to prevent the helium from boiling off too quickly.  A vacuum can surrounds both 
regions.  On the SolariX instrument, there is no liquid nitrogen, however, a liquid helium 
condenser allows the liquid helium to be recycled and therefore boil off at a lower rate.  A 
superconducting magnet is important in FT-ICR MS, because it has no electrical resistance, 
which means there is no heat produced from the magnet, therefore it does not lose energy as it 
continually conducts electricity and the magnetic drift is minimum121.  The ion cyclotron 
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frequency induced by the magnetic field is directly proportional to the strength of the magnetic 
field and inversely proportional to the mass to charge ratio.  The kinetic theory of the mean 
free path of ions explains why the ICR cell pressure must be kept very low116.  The mean free 
path is the distance that ions can travel without undergoing collisions with gas molecules.  The 
equation for the mean free path, L, is: 
(6)   𝐿 =
𝑘𝑇
√2𝑝𝜎
 , 
in which L is given in meters, k is the Boltzmann constant, T is temperature in K, p is the 
pressure and σ is the collision cross section.  Due to the small size of the cell (~4” diameter) and 
the relatively lengthy time (~1 s) ions spend in the cell, corresponding to an extensive ion path 
traveled, the mean free path must be very long, about forty miles at typical cell pressures.  Any 
residual gas in the cell may result in collisions, although the likelihood of this situation 
decreases with an increasing mean free path.  Collisions reduce the velocity and radius of the 
cyclotron orbit, which may result in losing ions from the cell12.  Space charge effects also may 
cause Coulomb peak broadening12. 
There are several options for the geometry of an analyzer cell, including open, closed, 
cylindrical and cubic122.  The Infinity cells in the Hakansson lab are closed cylindrical cells.  The 
purpose of the Infinity cell is to minimize z-axis ejection parallel to the magnetic field lines123.  
Eliminating these ejection events optimizes the excitation stage in the mass analyzer and 
provides more consistent signal abundancies123.  It also increases the signal to noise ratio by 
allowing for an increased excitation radius which in turn leads to more abundant image 
currents for detection123.  The trapping plate geometry of the Infinity cell simulates RF mirrors 
and a cell that is infinitely long123, which would lack z-axis ejection events.  The cell is divided 
into two pairs of electrodes located across from each other, one for excitation and the other for 
detection.   
 The three steps occurring in the cell in an MS experiment are trapping, excitation, and 
detection of ions.  The plates that assist these steps are seen in Figure 1.4.  The trapping plates 
axially confine the ions in the cell and allow them to move back and forth in a simple harmonic 
motion along the lines of the magnetic field124.  Ions are confined radially by their cyclotron 
motion12.  The overall ion motion in the xy-plane is a spiral-like movement with superimposed 
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magnetron motion, where the center of the cyclotron orbit is precessing around the cell116.  The 
cyclotron motion is induced by the Lorentz force (equation 7), which causes the ions to have an 
orbit perpendicular to the magnetic field, B, and the ion velocity v.12.  Other relevant factors 
include the ion’s mass, m and the charge q, which equals the elementary charge, e, multiplied 
by the number of elementary charges, z.  This outward centrifugal force may also be expressed 
as equation 8, in which r is the orbit’s radius.  Equating equations 7 and 8, and substituting ω, 
the angular frequency for v/r, with some rearrangement yields equation 9.  The cyclotron 
frequency can be measured very accurately because the frequency is measured and averaged 
over hundreds of rotations and therefore the mass to charge ratio may also be measured very 
accurately, in accordance with equation 9. 
(7)  F=𝑧𝑒𝒗 𝑥 𝑩 or F= 𝑞𝒗 𝑥 𝑩  
(8)  F =  
mv2
r
 
 (9)  ω=
𝑞𝐵
𝑚
   
On the other hand, the magnetron motion is governed by the magnetic field in 
combination with the electric field from the trapping plates12,122.  The magnetic field moves ions 
away from the cell wall, while the electric field moves ions away from the center of the cell12.   
In order for detection to occur, the ions are first excited with an RF signal across the 
excitation plates containing frequencies equal to the cyclotron frequencies of the ions124.  As 
the ions are being excited, they move according to the applied RF chirp into coherent ion 
packets with increased cyclotron radius at their m/z-dependent frequencies.  These coherently 
rotating ion packets induce an alternating signal in the detection plates124.  To minimize 
dephasing,  ions must be excited for a short amount of time (typically ~50 microseconds)116.  
The process of dephasing is comparable to T2 (spin-spin relaxation) dephasing in NMR 
spectroscopy except Coulomb repulsion occurs for the charged ions.  The analogy of T1 (spin-
lattice relaxation) in NMR is charge neutralization due to collisions95.   
Ions are detected by their image current: coherently excited ions generate an 
alternating current between the two detection plates in the cell12,124.  This current is converted 
to an RF voltage, which is displayed as a free induction decay (FID) or a transient with sine like 
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properties, providing time domain information about the detected ions124.  The time domain 
signal is converted to the frequency domain via Fourier transformation and the frequency 
domain spectrum is in turn converted to a mass spectrum via equation (9).  A unique aspect of 
image current detection is that it is non-destructive, so that the ions can be detected for a long 
time12.  As for any time domain spectroscopy, a longer transient results in higher resolution12.  
A long mean free path is essential for preventing collisions in the cell, thus resulting in longer 
transients and therefore higher resolution.   
 
Figure 1.4. Schematic diagram of the ICR cell parameters, particularly displaying Sidekick 
trapping voltages. 
 
The analyzer entrance voltage, EV1 (applied on the outside of the trapping plate facing 
the ion source, see Figure 1.4), gently attracts the ions into the cell and acts as a fine adjustor of 
the ion axial energy120.  The voltages PV1 and PV2 are applied to the inside of the trapping 
plates, causing ions to oscillate along the magnetic field lines.  The PV1 and PV2 voltages are set 
to the same polarity and confine the ions axially, so that they do not escape from the cell.  The 
VPV1(0), VPV2(0), VPV1(1), and VPV2(1) voltages (Figure 1.4), also applied to the inside of the 
trapping plates, are tuned for gated or dynamic trapping.  In dynamic trapping, the trapping 
potentials are gradually changed between two preset values, (0) and (1), for each trapping 
plate.  Without this gradual change, the trapped ions will have a wider energy range which, in 
VPV1(0) 
VPV1(1) 
VPV2(0) 
VPV2(1) 
23 
 
turn, decreases the m/z range125.  In the absence of dynamic trapping, Sidekick trapping is 
employed.  This kind of trapping is accomplished by utilizing an additional element, EV2 (Fig. 
1.4), at the entrance to the ICR cell.  A potential difference, DEV2, is applied between the two 
halves of the EV2 element, creating a voltage gradient across the cell entrance and thus 
facilitates ion cyclotron motion120.  P3 and PL3 are very important parameters because they 
control excitation of the ion packets.  PL3 controls the amplitude of the excitation waveform 
and P3 is the excitation time.  These ‘excite’ parameters control the ion cyclotron radius prior to 
detection.  If the ions are too close to the detection plates, mass spectral peaks may split, which 
will also happen if there are too many ions in the cell126.  If ions hit the detection plates, signal 
will quench.  On the other hand, a too small cyclotron radius leads to loss of signal.  On the 
Apex instrument, the PL3 parameter acts as a damper, however on SolariX, it corresponds 
directly to excitation amplitude.  Overall, the different cell voltages depend on one another and 
are therefore very sensitive to tuning.   
There have been several recent advancements in FT-ICR MS, including multiple cell 
designs.  One attractive design is the dynamically harmonized cell, put into production by 
Bruker Daltonics based on a design by  Professor Eugene Nikolaev who has shown a resolving 
power of about twelve million in a 4.7 T magnet127.  The electric field applied to an ICR cell is 
necessary to trap ions axially, however, this necessary field interrupts a potentially perfect ion 
motion, assuming a perfectly homogenous magnetic field and an absence of ion interactions 
with other ions or neutrals.  The electric field causes magnetron motion, which disturbs the 
cyclotron motion.  The z-axis amplitude also disturbs the cyclotron motion as an increase in z-
amplitude increases the electric field gradient128.  High z-amplitude ions rotate with lower 
velocities, which eventually results in de-phasing of ion packets as they are analyzed and 
detected128.  One way to lessen the effects of the electric field is to create an electric field with 
a hyperbolic shape, which allows the ion cyclotron frequency to be independent of axial ion 
motion in the cell128.  To create a hyperbolic electric field, Professor Nikolaev proposed to 
create a potential distribution that would be harmonic once the cyclotron field is averaged, 
rather than creating a harmonized field, a previous idea for other cell designs129-133.  To 
accomplish this feat, the Nikolaev cell is segmented with concave and convex parabolic shaped 
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slits, with the number of segments varying, in which a larger number of segments corresponds 
to a higher efficacy of averaging the potential128.  The National High Magnetic Field Laboratory 
(NHMFL) at Florida State University and the Pacific Northwest National Laboratory have been 
working separately on record 21 Tesla FT-ICR instruments134,135.  Recently, the NHMFL has 
successfully brought the 21 T magnet to field and it remains at field.  There has been a large 
push for higher magnetic fields due to their many advantages:  Increasing magnetic fields have 
a linear relationship with increased resolving power and acquisition speed and have a quadratic 
relationship with increasing dynamic range, ion trapping time, and ion kinetic energy136. 
 
1.4 Protein Post-Translational Modifications 
One of the primary reasons for the complexity of the proteome is the large number of 
post-translational modifications, which exponentially increase the size of the proteome137-139.   
 
 
A PTM is a covalent chemical modification to a protein and though the numbers vary, it is 
estimated that at least 80% of proteins in eukaryotes are modified with PTMs140.  PTMs play a 
large variety of roles in proteins and regulate protein function, as well as play a significant role 
in protein structure138.  PTMs significantly influence protein-protein interactions, cell signaling, 
Figure 1.5. The proteome is more 
complex than the genome or 
transcriptome, primarily due to an 
estimate of about one million 
PTMs2. Reprinted with permission 
from Munoz et al. Copyright 2014 
Angewandte Chemie2.  
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DNA repair, cell division, enzyme activity, activation and inactivation of proteins, and regulate 
cellular pathways.138,139,141.  Malfunctioning PTMs have been linked to a number of disorders 
and diseases126.  PTMs are generally of low abundance, dynamic, and labile, thus presenting 
numerous challenges18.  Mass spectrometry is an ideal tool for detection, identification, and 
characterization of PTMs due to its high sensitivity and versatility, including multiple MS/MS 
techniques.  Although there are over 300 different PTMs,137,142 this thesis will only focus on 
two: phosphorylation and phosphopantetheinylation. 
  
1.4.1 Protein phosphorylation 
 
According to the PTM statistics curator, which pulls updated statistics from the Swiss-
Prot knowledgebase, phosphorylation is the most frequent PTM143.  Phosphorylation is a 
prominent PTM in eukaryotes; estimates of phosphorylated proteins reach up to one third of all 
proteins in cells144-147.  Phosphorylation is found on serine, threonine, tyrosine, and occasionally 
histidine and involves the addition of a phosphate functional group to the side chain of these 
amino acids.   
 
Phosphorylation is thought to be the most understood PTM.  Phosphorylation is 
reversible; proteins are phosphorylated with kinases and dephosphorylated with phosphatases 
and there are hundreds of known kinases and phosphatases18.  Phosphorylation often changes 
protein structure, and thus function148,149.  Phosphorylation is vital because it is involved in 
many cellular processes, including signal transduction in different pathways and is responsible 
for regulation of different intracellular occurrences, such as gene expression and protein 
synthesis145,147,150-152.  The prominence and frequency of phosphorylation has opened up the 
field of phosphorylation enrichment.  Immobilized metal affinity chromatography (IMAC) 
utilizes metal ions such as Ga3+ or Fe3+ in a resin of either iminodiacetic acid or nitrilotriacetic 
Figure 1.6. Structure of a phosphorylated serine. 
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acid.  Negatively charged phosphate groups bind strongly to these metals and phosphoproteins 
or phosphopeptides can thus be isolated and later eluted under basic conditions153-157.  
Although IMAC is a popular technique, its overall specificity is somewhat low.  Metal oxide 
affinity chromatography (MOAC) is a similar method to IMAC, except that metal oxides, such as 
ZrO2 and TiO2, constitute the matrix158-160.  MOAC has higher specificity to phosphorylated 
peptides than IMAC.  More recently, a method has been developed that exploits monodisperse 
microsphere IMAC beads that contain a linker to phosphonate groups that chelate Ti4+ 161.  This 
approach combines IMAC and MOAC, has high specificity and is robust due to the structure of 
the materials that comprise this technique.  The microspheres are uniform and their surface is 
hydrophilic, thus minimizing non-specific adsorption.  The overall structure of the linkers and 
phosphonate group optimize the spatial orientation for phosphopeptide enrichment161.   
 
1.4.2 Protein phosphopantetheinylation 
 
 Phosphopantetheine (Ppant) is a much less common PTM than phosphorylation; yet it is 
just as vital to the proteins it is found on.  Ppant is covalently bound to acyl carrier proteins 
(ACPs) and peptidyl carrier proteins (PCPs) that are found in fatty acid synthases (FASs), 
polyketide synthases (PKSs) and non-ribosomal peptide synthetases (NRPSs)162,163.  Ppant 
chemical moieties are bound to serine residues and are long (about 2 nm) and flexible.  The 
Ppant terminal thiol group covalently binds substrates or natural product intermediates created 
in the FAS, PKS, or NRPS biosynthetic pathways164. 
 
 
Ppant’s length and flexibility allow abound reaction intermediates to interact with various 
protein domains and their active sites, so that elongation can occur to approach the structure 
of the final product.  The crystal structure of a Ppant transferase/PCP complex was recently 
solved and the structural basis for Ppant transfer was shown to be highly conserved through 
Figure 1.7. Structure of a 
phosphopantetheine arm.  
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organisms165.  Although there are no direct enrichment strategies for Ppant like there are for 
phosphorylation, there are several methods that utilize Ppant for discovery of novel natural 
products and biosynthetic pathways, however details about these techniques will be discussed 
in further detail in section 1.5 and Chapter 5166,167. 
1.5 Natural Products and their Biosynthetic Pathways 
1.5.1 Natural products as medicines 
 
Forty to over fifty percent of drugs on the market today derive from natural 
products168,169.  Nature continues to be a rich source for antibiotics, vaccines, anti-cancer drugs, 
as well as other drugs170,171.  Some well-known examples of natural products are penicillin from 
the skin of an orange or morphine, derived from opium, which is extracted from poppy 
seeds168.  One route for creating natural products for medicinal use is total synthesis, however, 
it is costly and challenging to synthesize complex and diverse structures.  An alternative route is 
chemoenzymatic synthesis, which is accomplished by feeding a biosynthetic enzyme and 
allowing it to create the natural product.  This process is much simpler than total synthesis, 
provided the biosynthetic pathway is known.  As a result, a field has developed containing 
biochemists and medicinal chemists who are focused on learning how biosynthetic pathways 
work, discovering novel biosynthetic pathways and novel natural products as well as the design 
and engineering of these pathways.  
 
1.5.2 Polyketide synthases and non-ribosomal peptide synthetases 
 
Polyketides constitute one class of natural products, biosynthesized in an assembly line-
like process by proteins called type I and type II polyketide synthases.  Polyketide synthases are 
megadaltons in size and consist of several polypeptides (modules), each containing multiple 
protein domains of varying function162.  Each module acts as an independent step in the 
assembly line-like chain elongation process, adding a two or three carbon unit to the growing 
natural product intermediate.  A PKS module consists of at least a ketosynthase (KS), an acyl 
transferase (AT), and an ACP domain, although they may have additional domains to promote 
structural diversity in the final natural products172.  PKS natural product diversity stems from 
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the order of each domain, and the combinations of modules and domains.  The assembly line 
starts with an acyl CoA, usually malonyl-CoA or methylmalonyl-CoA162.  The KS domain is about 
45 kDa and catalyzes a C-C bond formation through a Claisen condensation and results in two 
or three carbons from malonyl or methylmalonyl respectively being added to the growing 
intermediate162,173.  The AT is a 50 kDa domain that selects either malonyl or methylmalonyl 
and covalently transfers it to the Ppant of the ACP162.  The ACP is a smaller protein, about 12 
kDa, whose role is to tether and transfer the natural product intermediate to other domains 
and modules via the terminal thiol residue on the Ppant arm, which was previously described in 
section 1.4162,174,175.  The ACP is considered active or ‘holo’ when it is modified with Ppant and 
‘apo’ without the Ppant modification176,177.  There are several other domains which add 
diversity to the natural product intermediate such as ketoreductases, which reduce a β-ketone.  
Dehydratase domains dehydrate a β-hydroxy group to an α-β alkene, while enoyl reductases 
reduce the α-β alkene to an alkane162,174.  Finally, thioesterase (TE) domains hydrolyze and 
release the finished natural product, often as a cyclic molecule162,178. 
Non-ribosomal peptides are a related class of natural products, biosynthesized byNRPSs.  
Many natural products are hybrids of polyketides and non-ribosomal peptides, constructed 
from biosynthetic pathways with both PKS and NRPS enzymes, each enacting their part in the 
assembly line163.  Although non-ribosomal peptides are formed in a similar manner to 
polyketides, they show some key differences, including their building blocks.  NRPSs utilize 
activated amino acids or aryl acids rather than malonyl/methylmalonyl, thus adding diversity as 
all 20 amino acids can act as building blocks.  The NRPS domains are also different, although the 
required domains are comparable with those in PKSs:  Condensation (C), adenylation (A), and 
PCP are the three required domains in each module.  The C domain is similar to a KS in that it 
elongates the natural product intermediate, however it catalyzes C-N bond formation through 
transamidation rather than C-C bond formation163.  The intermediate acts as a nucleophile and 
is attacked by the free amino group from the upstream module intermediate163.  The A domain 
is comparable to the AT domain, as it selects an amino acid, activates the carboxylate end with 
ATP to make an aminoacyl-AMP group and then transfers it to the PCP domain163,176.  The PCP 
domain has the same function as the ACP and has a Ppant PTM.  Like PKSs, NRPSs have several 
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other domains that add diversity to the final product.  Epimerization domains epimerize amino 
acids from D to L or vice versa to control stereochemistry163,179.  N-methylation domains transfer 
S-methyl groups from S-adenosylmethionine to an amino group and thus strengthen the 
product by methylating all of the nitrogens on the peptide backbone, preventing proteolytic 
breakdown179.  Oxazoline and thiazoline rings may be reduced or oxidized by domains as 
well163.  An additional, yet rare, modification is formylation of the peptide N-terminus by a 
formylation domain163.  NRPSs also have a TE domain for hydrolysis and potential cyclization; 
however, they also have the option of a reduction domain for releasing the non-ribosomal 
peptide163.  The reduction domain reduces the C-terminus of the natural product to an 
aldehyde or alcohol163.   
 
1.5.3 Biochemical and biophysical methods for natural product characterization and discovery 
 
 Structural biology techniques such as X-ray crystallography and NMR spectroscopy have 
provided some insight into the partial structure of PKSs and NRPSs.  X-ray crystallography is a 
high resolution technique, but it cannot provide dynamic information and flexible proteins are 
difficult to crystallize.  Despite these limitations, X-ray crystallography has been successful at 
characterizing domain structures of natural product biosynthetic pathways or partial 
biosynthetic pathways, and a full structure of a fatty acid synthase is available180-185.  NMR 
spectroscopy is size limited, but useful for characterizing the natural products alone, including 
details such as stereochemistry186,187.  2D NMR can also determine the skeletal structure of 
natural products187,188 and may be employed to characterize the structure of acyl and peptidyl 
carrier proteins189-193.  Recently, vibrational spectroscopy has elucidated Ppant dynamics and 
determined its solution exposure in the 6-deoxyerythronolide B synthase (DEBS) biosynthetic 
pathway through installation of a thiocyanate vibrational spectroscopy probe194.  Cryo-electron 
microscopy (cryo-EM) is another emerging technique for characterizing large protein complex 
structures and their dynamics.  The power of this technique will be demonstrated in Chapter 3. 
 Mass spectrometry is an effective method in characterizing natural products and natural 
product intermediates, including enzyme-substrate intermediates.  MS can be utilized for high-
throughput screening and for developing libraries of natural products195.  Other MS methods 
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utilize the presence of the Ppant modification.  For example, CID or IRMPD will eject the Ppant 
modification from the ACP, creating a diagnostic ion of 261.1 Da (as long as the ACP is solely in 
its ‘holo’ state).  Meluzzi et al. further employed MS3 on a low resolution ion trap to create a 
high confidence method to measure the Ppant modification and any bound substrates164.  
Professor Neil Kelleher has developed several methods, including a Ppant ejection assay169 and 
proteomic  investigation  of secondary metabolism (PrISM), which targets the Ppant 
modification following MS/MS in unsequenced genomes167.  Another targeted approach for 
natural product biosynthetic pathway discovery is orthogonal active site identification system 
(OASIS), which targets TEs or ACPs with chemical probes166.  However, OASIS has not yet been 
applied to complex mixtures and uses a protein database to identify natural products, thus 
biasing the data towards known pathways.  The Hakansson lab also utilizes MS methods for 
characterization and discovery of natural products and biosynthetic pathways.  Top-down MS 
and IRMPD were utilized to characterize parts of the biosynthetic pathways for two natural 
products, curacin A and jamaicamide196,197.  Ultra high resolution has been employed to 
monitor active site occupancy for natural and unnatural building blocks, characterization of 
enzyme-substrate intermediates and products, and mining for the presence of an unsequenced 
biosynthetic pathway198-200.  
 
1.6 Dissertation Overview 
The research in this dissertation focuses on utilizing ultra high resolution bottom-up as 
well as top-down mass spectrometry coupled to LC to discern kinetics for the multisite 
phosphoprotein Sic1, to characterize several natural product biosynthetic pathways, and to 
develop a method to selectively identify unsequenced biosynthetic pathways.  Chapter 2 
determines the phosphorylation kinetics of Sic1, a protein with nine phosphorylation sites.  This 
chapter was a collaborative project with Professor Xiaoxia Nina Lin in the Chemical Engineering 
Department.  Mass spectrometry data, which will be compared to mathematical models, reveal 
that each site has a different phosphorylation rate, therefore supporting hypothesized switch-
like response of the protein.  In order to perform this work, a novel negative ion mode 
quantitative method was developed.  Chapter 3 determines and confirms the structural states 
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of PikAIII, the third module in the pikromycin biosynthetic pathway.  This chapter involved a 
collaboration with Professor Janet Smith, Professor David Sherman, and Professor Georgios 
Skiniotis of the Life Sciences Institute.  In this chapter, I improved and applied the previous 
method utilized in the Hakansson lab for confirming active sites and bound substrates.  My 
findings on the precise covalent protein state agreed with cryo-EM data collected in the 
Skiniotis laboratory.  This work has been published in a back-to-back article and letter in 
Nature201,202.  Chapter 4 further characterizes parts of the curacin and jamaicamide biosynthetic 
pathways via phosphopantetheine ejection.  This project is a collaboration with Professor Janet 
Smith in the Biological Chemistry Department/Life Sciences Institute.  Mass spectrometry 
confirmed the specific amino acids that are crucial for the structures of the unique natural 
product intermediates.  Mass spectrometry also confirmed the activity of a unique 
cyclopropanase, created by my collaborators.  Chapter 5 investigates discovery of novel 
biosynthetic pathways.  This chapter highlights a novel method which selectively detects and 
fragments peptides containing Ppant, more specifically the secondary phosphate in Ppant via 
IRMPD at 10.6 µm.  In addition, Chapter 6 summarizes all results and includes a section on 
future directions. 
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Chapter 2 
 
Site-Specific Kinetic Analysis of Mutant and Wildtype Sic1 
Phosphorylation 
 
 
2.1 Introduction   
Phosphorylation is a prominent protein post-translational modification (PTM) in eukaryotes; 
estimates of phosphorylated proteins reach up to one third of all proteins in cells1-4.  
Phosphorylation is significant because of its involvement in many cellular processes, including 
signal transduction in numerous pathways, and it is also responsible for regulation of various 
intracellular occurrences, such as gene expression and protein synthesis2,4-7.  Many signaling 
proteins have multiple phosphorylation sites and many biological systems show switch-like 
responses to external signals.  It has been hypothesized that multisite phosphorylation in proteins 
may be one mechanism underlying switch-like responses9-11.  Experimental observations12 
suggest that multisite phosphorylation can generate switch-like biological responses13,14, 
however, the mechanism for triggering such behavior is relatively unknown.   
Sic1, a protein found in budding yeast, has nine reported phosphorylation sites, which serve 
to trigger switch-like behavior during the cell cycle9,10.  Sic1 functions by inhibiting Clb5,6-Cdc28 
kinase complexes, which initiate DNA replication15-17.  Sic1 is phosphorylated by the Cdc28 kinase 
and phosphorylation of precisely six of the nine sites results in ubiquitination and subsequent 
degradation of the protein, a key step in regulating the cell cycle, specifically the transition from 
the G1 to S phase, as indicated in Figure 2.19,18,19.    
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One hypothesis is that the mechanism of the switch-like response is a chain-like reaction20,21.  The 
chain-like reaction is triggered by different phosphorylation states of the protein.  Sic1’s 
homologue, p27Kip1, is a tumor suppressor found in mammalian cells, where low levels of the 
protein are linked to various diseases, including cancers22,23.  Although the phosphorylation-
dependent degradation of Sic1 and p27Kip1 appears to be conserved, details regarding the 
degradation mechanism is yet to be discovered24. 
Coupling liquid chromatography (LC) to a mass spectrometer is a long standing technique and 
is customary in proteomics applications, including quantitation and detection of PTMs.  In 
complex mixtures, this practice decreases ion suppression in the mass spectrometer, causing the 
signal to noise ratio to increase and also increases peak capacity.  Mass spectrometry is an 
established technique for analyzing phosphopeptides and proteins, including quantitation,  
because it is accurate and can be done without chemical derivatization or labeling, which are 
employed in antibody recognition and Edman sequencing, two alternative techniques2,25.  Fourier 
transform ion cyclotron resonance mass spectrometry (FT-ICR MS) is a highly powerful technique 
because of its high resolving power and mass accuracy, arguably, the highest of all mass 
analyzers26-28.  The most common way of analyzing molecules in a mass spectrometer is in 
Figure 2.1. A schematic 
displaying the overall 
mechanism of Sic1’s transition 
from the G1 to S phase.8 
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positive ion mode for several reasons:  Standard LC columns have an upper pH limit around 7 but 
work best at lower pH, lending itself to peptide protonation.  In addition, collision induced 
dissociation tandem mass spectrometry (CID MS/MS) yields predictable fragmentation patterns 
for peptide cations and online databases and other informatics software therefore are based on 
positive ion mode mass spectra.  Most MS detectors are electron multipliers, which contribute a 
high noise level in negative ion mode due to the presence of free electrons, furthering the 
preferred choice of positive ion mode.  However, FT-ICR MS utilizes image current detection in 
which noise level is unaffected by polarity.  Additionally, acidic molecules, such as 
phosphorylated peptides and proteins, can be difficult to ionize in positive ion mode29,30.  
Analyzing acidic analytes in negative ion mode increases the sensitivity and lowers the limit of 
detection dramatically31,32.  High sensitivity and resolution are necessary to detect the peptide 
isotopes for label-free quantitation; therefore, all of the mass spectrometry work in this Chapter 
is conducted in negative ion mode, a novel aspect of this work.  Corona discharge can be a major 
issue in negative ion mode electrospray ionization, preventing stable ion signal33.  However, with 
source tuning, including the use of nebulizing gas, corona discharge was not a problem in this 
work. 
Here, we aim to quantitatively determine site-specific Sic1 phosphorylation kinetics to shed 
light on the mechanism behind the switch-like response.  All nine phosphorylation sites are 
characterized over six tryptic peptides and their phosphorylation rates are determined.  A new 
quantitation method is utilized with internal standards showing similar ionization efficiencies as 
the peptides of interest.   
 
2.2 Experimental 
Mutant (2p) and wildtype Sic1 with an N-terminal six residue histidine tag were 
overexpressed in E.coli and affinity purified via the His tag with a Ni-NTA column (Qiagen) 
following dialysis with Slide-a-Lyzer Dialysis Cassettes (Pierce).  Sic1 was phosphorylated with the 
kinase Cdc28 (gift from the Protein Expression Center of CalTech) and phosphorylation was 
quenched after 0, 5, 10, 20, 40, 80, and 180 minutes, respectively, with EDTA (Life Technologies).  
Each timepoint utilized 5 μL of 4 mg/mL kinase and 75 μL of 0.22 to 0.32 mg/mL Sic1 protein, 
depending on the replicate.  Sic1 mutant internal standard peptides (see Table 2.1) were 
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purchased from Anaspec, except for the singly phosphorylated 169-177 peptide, which was 
purchased from GenicBio.  Sic1 was denatured by heat at 95 degrees Celsius for 30 minutes, 
digested with trypsin (Promega) at 37 degrees Celsius overnight and quenched with 1.5 μL of 
formic acid (ThermoFisher Scientific).  Each Sic1 internal standard was dissolved in water to a 
final concentration of 2 mg/mL followed by 5:100 dilution.  Each sample for LC/MS analysis 
contained 2 µL of each peptide internal standard and 8 µL of digested and phosphorylated Sic1.   
Fifteen microliters of digested Sic1 with internal standards were injected onto a Synergi 
Hydro C18 hydrophilically endcapped 1 × 150 mm column with 4 µm particles (Phenomenex).  A 
gradient of 2-60% acetonitrile with 0.1% formic acid over seventy minutes was generated with 
an Agilent 1100 HPLC coupled to a quadrupole FTICR-MS (Apex or SolariX with 7T magnet, Bruker 
Daltonics).  Flow was at 50 µl min-1 and was diverted for the first 5 min of the run.  Buffer A was 
0.1% formic acid in HPLC-grade water (ThermoFisher Scientific), and buffer B was 0.1% formic 
acid in acetonitrile (ThermoFisher Scientific).  Data were gathered from m/z 200–2000 in negative 
ion mode.  Electrospray was conducted at 4,200 V with four scans per spectrum and a 256k 
transient.  External ion accumulation in a hexapole was 0.2 s and there was 1 ICR fill before 
excitation and detection.  External calibration was performed with HP tuning mix (Agilent).  Each 
experiment was run in triplicate. 
Peaks and peak areas were chosen and integrated with Data Analysis (Bruker Daltonics).  
Isotope percentages were calculated with Protein Prospector 
(http://prospector.ucsf.edu/prospector/mshome.htm).  All other calculations were carried out 
in Microsoft Excel.  The 2p mutant Sic1 protein has seven out of nine phosphorylation sites 
mutated to an alanine residue. 
Standard peptide Peptide Sequence Peptide Molecular Weight 
(monoisotopic mass in Da) 
2p mutant: 33-50-T33A V42L APQKPSQNLLPVTPSTTK 1906.052/ 1986.019 
2p mutant: 54-79-L57V S69A NAPVLAPPNSNMGMTAPFNGLTSPQR 2681.305/ 2761.272 
wt: 33-50-V42L TPQKPSQNLLPVTPSTTK 1936.063/2016.029/2095.996 
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wt: 54-79-L57V NAPVLAPPNSNMGMTSPFNGLTSPQR 2697.3/ 2777.267/ 2857.233 
wt: His tag+ 1-8- L13V MHHHHHHSSGVDVGTENLYFQSNATPS
TPPR 
3476.582/3556.548/ 
3636.514 
wt: 80-84 *13C 15N  SP*FPK 580.1/ 660.0663 
wt: 169-177-V170L DLPGTPSDK 928.4502/ 1008.416 
wt: 186-193 *13C 15N  NWNNNSP*K 978.1/ 1058.066 
Table 2.1. List of each standard peptide for the 2p and wt Sic1 phosphorylated peptides.  Red 
bolded residues indicate phosphorylation sites whereas italicized residues indicate substitutions 
in the internal standards.  Starred proline residues indicate 13C and 15N labels. 
2.3 Results and Discussion  
2.3.1 Label-free method development 
A label-free method was developed specifically to quantify Sic1 phosphorylated peptides, 
however, this method is applicable to nearly all peptides.  Internal standard peptides must have 
comparable ionization efficiencies to the peptides that are being quantified.  Valine and leucine 
residues only differ by a methyl group, thus Val to Leu or Leu to Val substitutions likely yield 
similar ionization efficiencies34.  Such substitutions are more cost-effective than isotopic labeling.  
The Sic1 2p mutant yields two phosphopeptides after trypsin digestion, both containing a valine 
or leucine residue.  Out of the six phosphopeptides (three with one phosphorylation site and 
three with two phosphorylation sites) from trypsin digestion of wt Sic1, the four larger peptides 
all contain leucine or valine.  For the remaining two wt phosphopeptides that lack leucine or 
valine, a proline is present and internal standard peptides were instead doubly labeled with 13C 
and 15N at this residue.  The Leu to Val and Val to Leu substitutions were validated for differences 
in ionization efficiencies.  The 33-50 peptide ionization efficiency difference was 7 ± 4%, the 54-
79 peptide ionization efficiency difference was 9 ± 23%, the His1-8 peptide ionization efficiency 
difference was 39 ± 3%, and the 169-177 peptide ionization efficiency difference was 9 ± 6%.  
Example extracted ion chromatograms (EICs) used to calculate the ionization efficiency 
difference for the 33-50 peptide are displayed in Figure 2.2.  The majority of these ionization 
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efficiency differences are minor; therefore, the Val to Leu and Leu to Val substitutions are an 
acceptable method of quantitation.   
 
  
Figure 2.2. Comparable EICs were seen for the 33-50 peptide and the 33-50 V42L substitution 
internal standard. 
 
Many conventional methods quantify a single peak height or peak area per peptide.  
However, ultra-high resolution mass spectrometry allows for the resolution of multiple isotopic 
peaks.  Therefore, in this study, peak areas of the first three isotopes are included to improve 
quantitative accuracy.  The first three isotopes represent different percentages of the total 
number of observable isotopes for each peptide as this number is mass dependent.  These 
percentages were calculated with Protein Prospector’s MS Isotope function.  For example, a 600 
Da peptide’s first three isotopes represent ~100% of the total isotope distribution; however, a 
2800 Da peptide’s first three isotopes only represent ~72% of the total isotope distribution.  To 
calculate a peptide’s concentration, the sum of the three peak areas is multiplied by this 
percentage.  This number is then divided by the peptide standard’s first three isotopes, with 
percentage taken into account, and is then multiplied by the standard peptide’s concentration.  
Additionally, all mass spectrometry data were collected in negative ion mode.  Although negative 
ion mode is unusual for protein analysis, phosphorylated peptides and other acidic peptides 
ionize more readily in negative ion mode than in positive ion mode.  Traditionally, a base is added 
to the spray solvent in negative ion mode to promote deprotonation.  In our developed method, 
0.1% formic acid was added to the LC solvents, because of the pH limit of the LC column.  The pH 
of 0.1% formic acid in water is about 2.7, whereas acidic side chains with a phosphorylation 
modification can have a pKa lower than 1.5; therefore, phosphorylated peptides may still 
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deprotonate in acidic solvents and mobile phases35.  The advantage of negative ion mode over 
positive ion mode is shown in Figure 2.3 for one of the peptides of interest.  Similar abundance 
improvement was shown for all Sic1 phosphopeptides.  The developed novel method is more 
accurate than utilizing a single peak area, because it includes more of the data available and thus 
more accurately represents the data. 
 
Figure 2.3. EICs from positive (in blue) and negative (in red) ion mode LC/MS of the Sic1 54-79 
peptide.  The serines in bold and red constitute the phosphorylation sites  The doubly 
phosphorylated (2p) peptide was only detected in negative ion mode and both the unmodified 
and singly phosphorylated (1p) peptides ionize more efficiently in negative ion mode.  Positive 
ion mode EICs were collected by Dr. Hangtian Song. 
 
2.3.2 Site-specific phosphorylation kinetics for the Sic1 2p mutant 
 The Sic1 2p mutant has two phosphorylation sites: T45 and S76; the other seven 
phosphorylation sites are mutated to alanine.  The purpose of determining the 2p kinetics was 
to establish a protocol for quantitative negative ion mode LC/MS.  The concentration of each 
unmodified and phosphorylated peptide was determined over seven timepoints.  Figure 2.4 
illustrates the kinetic curves for the 33-50 T33A peptide and the 54-79 S69A peptide, respectively.   
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Figure 2.4. Phosphorylation kinetics of the Sic1 2p mutant for the 33-50 peptide (top) and the 
54-79 peptide (bottom).  The absolute concentration of the unmodified and singly 
phosphorylated peptides is shown as a function of kinase exposure time.  The 2p mutant was not 
subjected to denaturation prior to trypsin digestion. 
 
Phosphorylation occurs at a faster rate on S76 than on T45.  Each phosphorylation event does 
not occur at the same rate, which was not necessarily expected.  A switch-like response could 
indicate all phosphorylation events occurring simultaneously or occurring at different times, 
including a chain-like reaction.  However, the 2p mutant provides limited data, merely two rates; 
therefore, it was necessary to collect further data with the Sic1 wildtype protein. 
 
2.3.3 Protein denaturation effects 
An unexpected result for the 2p data shown in Fig. 2.4 was the observed initial increase in 
abundance of the non-phosphorylated peptide.  We hypothesized that the trypsin digestion 
efficiency may be different for the different phosphostates of the protein due to structural 
changes and differences in flexibility occurring at the onset of multisite phosphorylation36: A 
protein with little or no exposure to kinase may be less flexible with a tighter fold than the same 
protein with more exposure to kinase, thus influencing trypsin digestion efficiency.  Similar 
kinetic curves were initially also observed for wildtype Sic1.  Following these observations, we 
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experimented with different protein denaturation methods prior to trypsin digestion.  A 
comparison between no denaturation, urea-based denaturation, and heat denaturation prior to 
trypsin digestion is shown in Figure 2.5 for the 33-50 peptide from the wildtype protein.  With 
denaturation, the overall concentration of the peptides increased, although there was a larger 
effect for the shorter kinase exposure times.  
 
Figure 2.5. A comparison between three protein denaturation options prior to trypsin digestion.  
Heat denaturation yields a lower error and higher overall concentration of Sic1 peptides. 
 
Denaturation with heat yielded higher peptide concentrations than denaturation with urea.  Even 
after dilution and desalting via LC, the urea concentration is still high, thus lowering peptide signal 
to noise ratios.  Therefore, heat denaturation appears to be the most effective Sic 1 denaturation 
method and we utilized this approach for the data shown below.   
 
2.3.4 Site-specific wildtype Sic1 phosphorylation kinetics 
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The rate of phosphorylation for each tryptic phosphopeptide from wt Sic1 was determined in 
the same manner as the 2p mutant.   Interestingly, phosphorylation of peptides with two 
phosphorylation sites showed faster kinetics than phosphorylation of peptides with only one site.  
T33 and T45 in the 33-50 peptide both show relatively fast phosphorylation rate and have very 
similar rates of phosphorylation.  For the 1-8 and 54-79 peptides (both with two phosphorylation 
sites), one site showed faster kinetics than the other.  Although it has not yet been determined 
which site is fast and which is slow, previous studies showed that T5 and S76 contribute more to 
Sic1’s degradation than T2 and S6910.  An electron capture dissociation (ECD) experiment would 
be able to determine the identification of the phosphorylation site for the 1p curve for both the 
54-79 and 1-8 peptide.  The experiment would also be able to determine if it was a mixture of 
both phosphorylation sites.  Fraction collection and ECD have been attempted; however, the 
peptides of interest were not abundant enough for a successful ECD experiment.  S191 in the 
186-193 peptide shows a faster phosphorylation rate than the other peptides with one 
phosphorylation site, but S191 kinetics is still slower than the kinetics of one of the 
phosphorylation sites in the 33-50 and the 1-8 peptide, both are peptides with two 
phosphorylation sites.  S80 in the 80-84 peptide and T173 in the 169-177 peptide showed low 
phosphorylation rates.  Each kinetic curve is illustrated in Figure 2.6.  These results imply that 
there is a specific order to the phosphorylation and that certain sites are more significant to Sic1’s 
degradation.  The 2p mutant and the wt are comparable in that not all sites phosphorylate at the 
same rate.  Although this observation does not prove the hypothesis that a chain-like reaction 
leads to the degradation of Sic1, it supports the possibility that the phosphorylation of one site 
triggers the phosphorylation of the next site.  Mathematical modeling to fit the kinetic curves will 
lend further support or negation of this hypothesis.  The mathematical modeling will be 
performed to measure the ultrasensitivity response of Sic1, as multisite phosphorylation may 
lead to ultrasensitive responses10,11,37. An ultrasensitive response in a system is more sensitive to 
stimuli change than a standard system and is characterized by the Hill coefficient, nH, producing 
sigmoidal curves instead of Michaelis-Menten hyperbolic curves.  For a standard hyperbolic 
curve, nH = 1, and the number increases for ultrasensitive responses.  Previous data 
demonstrated that Sic1 binding to Cdc4 (Figure 2.1) results in an ultrasensitive response8.  
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Although our wildtype kinetic data have not yet been fitted, mathematical modeling will be 
performed in the future to further elucidate the switch-like response of Sic1. 
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Figure 2.6. Phosphorylation kinetics of all nine phosphorylation sites in wt Sic1.  The absolute 
concentration of the unmodified, singly, and doubly phosphorylated peptides are shown as a 
function of kinase exposure time.   
Another observation to note is that the overall total amount (sum of the amount of non-
phosphorylated, singly- and doubly-phosphorylated peptide) for the 54-79 peptide decreases 
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with kinase exposure time and that there is a dramatic decrease in the total amount of the 33-
50 peptide.  One hypothesis is that a third, non-specific, phosphorylation event occurs, because 
both peptides have multiple serine and threonine residues in addition to the two known (proline-
directed) sites.  A third phosphorylation event was not observed for the 54-79 peptide, thus the 
overall loss of this peptide is unaccounted for.  The LC autosampler was chilled and the time 
points were collected in a random order, so there is no evidence of peptide degradation with 
time.  A third phosphorylation event was, however, observed for the 33-50 peptide through 
precise addition of the mass corresponding to HPO3 (with less than 1 ppm error).  The abundance 
of a species with this specific mass increases with kinase exposure time.  The mass of this 
presumably triply phosphorylated 33-50 peptide does not correspond to any other possible 
tryptic peptide from Sic1.   
 
Figure 2.7.  Evidence demonstrating an additional, non-specific phosphorylation event on both 
the wildtype 33-50 peptide (total of three phosphorylations), and the 33-50 2p mutant peptide 
(total of two phosphorylations).  CID MS/MS (top, 2p peptide after 180 minutes of kinase 
exposure) showed loss of phosphoric acid, as expected.  Raw data abundances (without 
normalizing to internal standard as no 3p standard was available) illustrate how the triply 
phosphorylated wildtype peptide abundance increases with kinase exposure time (bottom).   
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Although the low abundance of the putative triply phosphorylated peptide was challenging for 
tandem mass spectrometry, further identity evidence was provided through the observation of 
phosphoric acid loss upon collision induced dissociation (CID) for an analogous doubly 
phosphorylated peptide for the Sic1 2p mutant (with only one phosphorylation site), as seen in 
Figure 2.7 (top).  Lack of additional peptide sequence information may be attributed to CID being 
performed in negative ion mode, which is known to primarily provide neutral losses and 
unpredictable sequence information38.  The putative triply phosphorylated peptide was collected 
from off-line LC for an ECD experiment.  A successful ECD experiment would yield fragments 
localizing the phosphorylation sites.  However, the collected LC fraction was a mixture with 
additional abundant peptides, rendering the peptide of interest challenging to isolate and 
fragment.  Additionally, the peptide of interest’s abundance was too low for a successful ECD 
experiment.   
In order to ensure reproducible results, the entire set of experiments, including protein 
preparation and phosphorylation, was repeated a second time for the wildtype protein with the 
same protocol.  The protein concentration was higher when measured with the Nanodrop, 0.33 
mg/mL to the above data’s 0.22 mg/mL, but overall the curves are very similar, demonstrating 
reproducibility.  Notably, throughout both replicates, there are points where the concentrations 
dip and increase again.  Comparing one replicate to another, the dips occur at different points, 
indicating these unexpected changes in concentration are due to experimental error, perhaps a 
poor signal to noise ratio.  
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Figure 2.8.  A second replicate of the phosphorylation kinetics of all nine phosphorylation sites in 
wt Sic1.  The absolute concentration of the unmodified, singly, and doubly phosphorylated 
peptides are shown as a function of kinase exposure time.   
 
2.4 Conclusions 
A negative ion mode quantitative method was developed to investigate the 
phosphorylation kinetics and mechanism of the yeast protein Sic1.  Valine to leucine or leucine 
to valine substitutions allowed for a set of internal standard peptides with a 14 Da mass 
difference without significantly affecting the ionization efficiency of the standard peptides.  To 
establish the quantitative technique, site-specific phosphorylation was quantified for the Sic1 2p 
mutant and phosphorylation kinetics were established.  The two phosphorylation sites in the 2p 
mutant have very different rates of phosphorylation.  The wildtype protein has nine 
phosphorylation sites; kinetics were determined for each phosphopeptide.  Each 
phosphorylation site showed a different kinetic rate and the fastest rates show good agreement 
with previous studies10 that declared T45, S76, T5, and T33 were most significant for Sic1’s 
degradation.  Future work includes determining the site of the third putative phosphorylation 
site on the 33-50 peptide, determining the 1p phosphorylation site(s) on the 54-79 and 1-8 
peptides, and comparing the phosphorylation rates with mathematical models.  The models will 
determine the ultrasensitive response of Sic1, which will clarify the mechanism of the switch-like 
response of this multisite protein. 
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Chapter 3  
Improved LC/FT-ICR MS for Interrogation of Natural 
Product Biosynthetic Enzymes “In Action” 
 
3.1 Introduction 
 Nature is a rich source of antibiotics, vaccines, anti-cancer drugs, as well as other 
medicines1,2.  Many of these natural products are synthesized by protein complexes called 
polyketide synthases (PKSs).  The first modular polyketide synthase gene was sequenced in the 
early 1990s3,4.  Streptomyces venezuelae is a bacterium found in soil and is known to express 
multiple PKSs.  The pikromycin (PikA) biosynthetic pathway is an example of a type I PKS in S. 
venezuelae.  Type I PKSs are modular in construction, whereas type II PKSs are composed of 
separate domains, and type III PKSs have a similar construction to type II PKSs, except that they 
are ACP-independent5,6.  The PikA biosynthetic pathway generates three natural products, 10-
deoxymethynolide, narbonolide, and pikromycin, the first macrolide antibiotic to be isolated7,8.  
Although total synthesis of pikromycin is possible, it involves many steps and yields less than 5 
mg9.  Conversion of narbonolide to pikromycin is possible with fewer steps (five compared with 
over twenty), however, neither product is biologically useful10,11.  As an alternative to total 
synthesis for creating biologically relevant compounds, chemoenzymatic synthesis can produce 
a higher yield and is a simpler process when a biosynthetic pathway is known12.  The pikromycin 
system is reportedly the best characterized PKS and is known as a model system since its initial 
isolation and biochemical characterization of the biosynthetic proteins13.   
The PikA pathway (Figure 3.1) consists of four genes expressed into seven polypeptide 
modules.  Like other type I PKSs, a module minimally consists of three protein domains: a 
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ketosynthase (KS), an acyl transferase (AT) and an acyl carrier protein (ACP)14.  The KS domain 
catalyzes C-C bond formation through a Claisen condensation and results in addition of two or 
three carbons from malonyl or methylmalonyl (MM), respectively, to the growing natural 
product intermediate14,15.  The AT selects either malonyl or methylmalonyl from their 
corresponding coenzyme As and transfers it to the ACP14.  The ACP’s role is to tether and 
transfer the natural product intermediate to other domains and modules via a thiol residue on 
a phosphopantetheine (Ppant) post-translational modification arm6,14,16.  Structural and 
mechanistic insights into individual PikA domains have been gained, including the 
thioesterase17-19 and the docking domains between the modules PikAIII and PikAIV (Fig. 3.1)20.  
Further, docking domains,21 ACP,22 and ketoreductase (KR)23 domains have been structurally 
characterized in the 6-deoxyerythronolide B synthase (DEBS), a similar PKS, pathway that 
produces the antibiotic erythromycin.   
 
Figure 3.1. The layout of the pikromycin biosynthetic pathway, including 12 and 14-membered 
products and substrate units24. 
PikA, as well as other biosynthetic pathways, are being explored and investigated for the 
potential to create novel antibiotics11.   Although the products naturally generated from the 
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PikA system are not medically useful in humans, their general structures are an ideal starting 
point for other useful antibiotics and PikA is unique in that it creates 12 and 14-membered 
rings11.  Additionally, the PikA system has significant flexibility in both the substrate choice and 
enzyme order, including acceptance of domains from other systems such as the DEBS 
biosynthetic pathway, furthering its utility to generate novel natural products11,25.  Site-directed 
mutagenesis in ATs has been shown to alter the AT substrate specificity26,27.  Further work with 
mixing and matching DEBS and PikA substrates and domains has provided insight into specificity 
differences between individual modules25,28-30.  For example, module five of the PikA system is 
thought to be a ‘gatekeeper’ because of its strict specificity, whereas module 6 is much less 
specific and is thought to be more amenable to the biosynthesis of novel natural products25,31.  
The domain order is very important for the product’s structure; therefore, combinatorial 
biosynthesis with rational design is vital to novel drug design4,32-36.  Mixing and matching 
domains and modules from different biosynthetic pathways has resulted in hundreds of novel 
natural products; however, the failures far outweigh the successes12,37-39.  Many of these 
failures arise because certain domains have affinities for other domains, and each domain has a 
degree of substrate specificity40-43.  The relationship between each domain that allows for 
sequential steps in the creation of natural products has been unknown41.  Further insight into 
these systems is needed to create more successful antibiotics and other medicines.  
Determining the structure of PKSs would allow for more thoughtful and intelligent design of 
substrates and domain and module rearrangement.  There have been multiple PKS structural 
models; however, until recently, the models have not been proven.  The head-to-tail and the 
head-to-head models were based on the mammalian fatty acid synthase (mFAS) structure, in 
the belief that mFAS had similar architecture to PKSs44,45.  The double helix model, proposed by 
Professor Peter Leadlay, challenged the previous models, accounted for the dimeric structure, 
and placed the ACP in the center, so that it was accessible to all domains46.   
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Figure 3.2. Past proposed models of PKSs. A. The head-to-tail model and the head-to-head 
model. B. The double helix model. Adapted from Smith and Tsai44 with permission of The Royal 
Society of Chemistry. C. The mFAS model.  Figure adapted from Maier et al47. Reprinted with 
permission from AAAS.  
In 2008 the crystal structure of a mFAS was solved with 3.2 Å resolution and was found to 
resemble an ‘X’ shape47,48.  Under the assumption that a fatty acid synthase and PKS had similar 
structures due to their homology, the model structure for a PKS changed yet again.  The first 
structure of an entire PKS module, pikromycin module 5 (PikAIII), was obtained by our 
collaborators via high resolution cryo-electron microscopy (cryo-EM).  Here, we show Fourier 
transform ion cyclotron resonance mass spectrometry (FT-ICR MS) to determine and confirm 
covalent protein states for each structural form found.  In order to achieve these results, 
69 
 
improvements were needed to a previous mass spectrometry assay for characterizing PKS 
active site peptides. 
3.2 Experimental 
3.2.1 Protein preparation 
Proteins were prepared by J. R. Whicher in the following manner: All expression plasmids, 
except ACP4–PikAIII(C209A/ΔACP5) (see section 3.3.3), were expressed in Escherichia coli Bap1 
cells49 to produce holo-ACP.  ACP4–PikAIII(C209A/ΔACP5) was expressed in BL21 (DE3) to 
produce apo-ACP. Transformed bacteria were cultured at 37 °C to an OD600 nm = 1 in 0.5 L of TB 
media with 50 µg/ml kanamycin. After incubation at 20 °C for 1 h, cells were induced with 
200 µM isopropyl-β-D-thiogalactoside (IPTG) and allowed to express for approximately 18 h. 
Cell pellets were re-suspended in 300 mM NaCl, 10% glycerol with either 50 mM HEPES 
pH 8 (buffer A pH 8; ACP4–PikAIII(C209A/ΔACP5)) or 50 mM HEPES pH 7.4 (buffer A pH 7.4; all 
other constructs) containing 0.1 mg/ml lysozyme, 0.05 mg/ml DNase, 2 mM MgCl2 and 20 mM 
imidazole. Cells were lysed by sonication, centrifuged, and the supernatant was loaded onto a 
5 mL HisTrap column (GE Healthcare). A gradient of 15–300 mM imidazole in buffer A over 10 
column volumes was used to elute the proteins. 
Proteins were dialyzed into 50 mM HEPES pH 7.4, 100 mM NaCl before substrate 
loading. The holo-PikAIII and PikAIII(ΔACP) samples were not incubated with substrate. For the 
MM–PikAIII sample, 1 μM holo-PikAIII was incubated with 500 μM MM–CoA for 30 min at room 
temperature. 
To prepare ACP4–PikAIII(C209A/ΔACP5), in which the ACP4 was loaded with pentaketide, 
6 μM apo-ACP4–PikAIII(C209A/ΔACP5) from the first gel filtration column was incubated with 
100 μM pentaketide–CoA, 10 μM SVP (a non-specific phosphopantetheinyl transferase)50, 
10 μM MgCl2 for 2 h at 30 °C in buffer A pH 8, and re-purified with a second HiPrep 16/60 
Sephacryl S300 HR column equilibrated with 50 mM HEPES pH 6.8, 300 mM NaCl, 10% glycerol 
(buffer A pH 6.8). The peak fraction was collected from the second gel filtration and dialyzed 
into 50 mM HEPES pH 6.8, 100 mM NaCl. 
 
3.2.2 Mass spectrometry sample preparation  
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Samples were prepared for MS analysis by Narayan, A. R. H. according to the following 
procedure: Twenty-five μl of 2 μM holo-PikAIII, 25 μl 2 μM MM–PikAIII, 25 μl 2 μM 
pentaketide–ACP4–PikAIII(C209A/ΔACP5), and 25 μl 2 μM holo-ACP4–PikAIII(C209A/ΔACP5) were 
diluted with 20 μl of 250 mM ammonium bicarbonate pH 8.0. Trypsin in 50 mM acetic acid was 
added in an enzyme: substrate ratio of 1:10. Proteolysis was allowed to proceed for 15 min at 
37 °C followed by addition of formic acid (pH 4). Samples were stored at -20 °C until analysis. 
 
3.2.3 LC/FT-ICR MS analysis 
Forty-five μl of sample were injected onto a Synergi Hydro C18 hydrophilically end-
capped 1 × 150 mm column with 4 µm particles (Phenomenex).  A gradient was generated on 
an Agilent 1100 HPLC. This gradient was as follows (with isocratic elution between 40 and 
50 min): 0 (98,2), 20 (70,30), 40 (50,50), 50 (50,50), 55 (30,70), 70 (2,98).  Values are provided 
as time (%A, %B) over a total run time of 90 min.  Flow was at 50 µl/min and was diverted for 
the first 5 min of the run.  HPLC solvent A was 0.1% formic acid (ThermoFisher Scientific) in 
HPLC-grade water (ThermoFisher Scientific), and solvent B was 0.1% formic acid in acetonitrile 
(ThermoFisher Scientific).  The LC was coupled to a quadrupole FTICR-MS (SolariX with 7T 
magnet, Bruker Daltonics).  Data were gathered from m/z 200–2,000 in positive ion mode.  
Electrospray was conducted at 4,500 V with four scans per spectrum and a 256k transient.  
External ion accumulation in a hexapole was 0.2 s and there was 1 ICR fill before excitation and 
detection. External calibration used HP-mix (Agilent).  PikAIII peptide products were detected 
over three samples in separate runs. 
 
3.2.4 Cryo-EM preparation and analysis 
For details regarding the cryo-electron microscopy preparation and analysis, please see the 
methods sections of the published papers from where this chapter is derived51,52.   
3.3 Results/Discussion  
3.3.1 Cryo-EM details and LC/FT-ICR MS improvements 
Single particle cryo-EM was applied to determine the structure of the entire PikAIII 
module.  Cryo-EM determined the three dimensional structure of different physiological states 
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while FT-ICR MS determined and confirmed covalent protein states.  Traditional electron 
microscopy suffers from poor signal to noise ratio, due to bond damage and formation of free 
radicals53.  Cryo-EM reduces damage caused to the sample by six-fold, due to the low 
temperatures and the glass-like ice layer that forms on the sample53.  Because the cryogenic 
temperatures freeze the sample into place, cryo-EM is a promising alternative technique to X-
ray crystallography, which is unable to resolve proteins that have flexible areas.  Single particle 
cryo-EM collects two-dimensional images of the sample at different orientations which are 
combined into a three-dimensional reconstruction of the sample’s structure53.  If an atomic 
model of the sample is available, it may be fitted into the density map, which greatly expands 
the structural information53.  The resolution of the PikAIII samples ranged from 7.3-11.6 Å, 
which is very high for cryo-EM.  FT-ICR MS is known for its ultra-high resolution and high mass 
accuracy, an ideal instrument for confirming each protein state.  PikAIII was the analyte of 
choice, because it can be produced readily in a pure form and our collaborators have expertise 
in the synthesis of its substrate intermediate54.  
Previous research in the Håkansson lab has involved liquid chromatography (LC)/FT-ICR 
MS of natural product biosynthetic pathways42, however improvements to the previous LC 
method were necessary to confirm each PikAIII active site.  Table 3.1 summarizes these 
improvements.  Previously, all cysteines were reduced and alkylated prior to digestion.  In the 
current protocol, the cysteines are left unmodified, because the ketosynthase domain’s active 
site peptide binds to its substrate via a cysteine.  The trypsin digest time was reduced to 
minimize chances of substrates hydrolyzing from their active sites.   An LC column more suitable 
for peptides was employed, with smaller particles and diameter, and with C18 particles rather 
than C4 particles.  Accordingly, the LC column’s size resulted in the selection of a lower flow 
rate.  With the slower flow, a longer LC gradient was chosen.  Additionally, a linear gradient 
resulted in co-elution of many peptides, so a step-wise gradient was developed. 
Protocol Differences Previous Protocol Current Protocol 
Cysteine chemistry Reduced and alkylated Unmodified 
Trypsin digest time 15-45 minutes 15 minutes 
Column C4 2 x 250 mm 300 μm 
particles 
Hydrophilically endcapped C18 
 1 x 50 mm 4 μm particles 
Flow Rate 200 μl/min 50 μl/min 
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LC gradient Linear, 40 minutes Stepwise, 90 minutes 
 
Table 3.1. A summary of the implemented sample preparation and LC improvements optimized 
for maximum active site peptide determination.  
 
3.3.2 Holo vs. apo PikAIII structure determination and LC/FT-ICR MS confirmation 
 The overall structure of PikAIII, as determined with cryo-EM, is arch-like, with the KS at 
the top, followed by the AT domains on either side, with the KR domains at the bottom.  The 
overall structure was unexpected, as the expected PikAIII structure was more linear, analogous 
to the mFAS structure in Figure 3.2C.  Instead, the AT domains are rotated 120 degrees, relative 
to the mFAS crystal structure and there is a single active site chamber in PikAIII, although there 
are two in the mFAS structure.  The cryo-EM data also revealed the existence of two separate 
conformers with approximately equal amounts of each; one in which the ACP is near the KS and 
AT domains, and another in which the ACP is at the bottom of the arch, near the KR domains.  
One hypothesis explaining the two conformers is that one has an apo ACP and one has a holo 
ACP, i.e., without and with the Ppant modification, respectively.  However, cryo-EM data alone 
cannot confirm or deny this hypothesis.  LC/FT-ICR MS (Fig. 3.4) determined that the relative 
amounts of apo and holo peptide were about 3% and 97% respectively, refuting the hypothesis.  
Alternatively, the two different conformers provide evidence that the ACP moves around the 
overall architecture.   
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Figure 3.3. Top: Cryo-EM images of holo PikAIII.  The ACPs are shown in orange.  Bottom: 
Reconstructed crystal structures of holo PikAIII using DEBS module 5 KS, module 5 AT, module 1 
KR, and an NMR structure of DEBS module 2 ACP.  There are two completely different 
conformers, with the left one appearing in about 57% of particle projections, whereas the 
conformer to the right appeared in about 43% of particle projections.  Data generated by S. 
Dutta. 
 
 Figure 3.4. Partial mass spectra of ACP5 active site peptides from LC/FT-ICR MS of trypsin 
digested PikAIII.  Both apo and holo ACP5 peptides were observed in two different charge 
states.  Relative quantitation was performed by integrating the peak areas of all isotopes with a 
signal to noise ratio of three or higher. 
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3.3.3  PikAIIIΔACP5 and ACP4-PikAIII(C209A/ΔACP5) structure determination and LC/FT-ICR MS 
confirmation 
 To examine how an upstream ACP interacts with its downstream module, a PikAIII 
construct lacking its ACP (PikAIIIΔACP5) was first expressed.  The overall structure was 
comparable to the holo PikAIII conformers shown above; however, the KR domains were 
rotated by 165°, indicating that ACP5 has a strong influence on the structure and orientation of 
the module.  Another construct was then expressed in which ACP4 from the preceding PikAII 
(module 4) was fused to the N-terminus of PikAIIIΔACP5 via a flexible linker.  The KS active site 
cysteine was also mutated to an alanine, to prevent immediate transfer of the PikAII-generated 
pentaketide intermediate, in vitro loaded to ACP4, to the KS.  For this construct, the ACP4 was 
located outside of the arch, at the top, bound to the KS, as shown in Figure 3.5.  LC/FT-ICR MS 
(Figure 3.6) confirmed that the mutated active site KS peptide was unmodified and that the 
ACP4 active site was loaded with pentaketide.  The location of ACP4 suggests that the 
pentaketide intermediate strongly drives the docking of ACP4 at the KS active site entrance.   
 
Figure 3.5. Cryo-EM structure of ACP4-PikAIII(C209A/ΔACP5).  Note that the KR domains are 
rotated inward 165° compared with holo PikAIII (Fig. 3.3).  ACP4 (displayed in red) is outside of 
the arch, bound to the KS.  The figure to the right shows the close proximity of the KS and ACP4 
active sites, about 28 Å apart. Data generated by S. Dutta. 
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Figure 3.6. Partial mass spectra of ACP4-PikAIII(C209A/ΔACP5) active-site peptides from LC/FT-
ICR MS of trypsin digested protein.  Active site peptides include KS C209A and ACP4 in apo, holo, 
and pentaketide- loaded states. 
 
3.3.4 MM-loaded PikAIII structure determination and LC/FT-ICR MS confirmation 
 The next step was to explore how ACP5 interacts with the KS active site when the 
extender unit, methylmalonyl is introduced.  For this purpose, holo PikAIII was incubated with 
500-fold excess MM.  LC/FT-ICR MS unambiguously confirmed that both the AT and ACP active 
sites were loaded with MM (Figure 3.7).  Cryo-EM data showed that the overall architecture of 
MM-loaded PikAIII is similar to holo PikAIII, however, ACP5 was only observed in one location in 
the MM-loaded protein, below the KS and next to the AT domains (Figure 3.8).  This new 
location provides evidence that ACP5’s location is based upon its attached substrate.  Although 
the KS is not involved in MM loading, the KS and ACP5 active sites are only 25 Å away from each 
other following MM loading, indicating the KS is ready to play its role.  This structure revealed a 
second active site entrance at the bottom of the KS.  Compared with the crystal structure of the 
DEBS KS-AT didomain, the loop surrounding the active site entrance has very low sequence 
conservation.  Furthermore, the mFAS has a single active site entrance, so a second entrance 
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was unexpected.  The second active site entrance allows for shuttling of substrates to and from 
the KS and may also allow for domain or module ‘skipping’, as seen in the Pik and DEBS 
systems55,56.   
 
Figure 3.7. Partial mass spectra of AT and ACP active-site peptides from LC/FT-ICR MS of trypsin 
digested MM-loaded PikAIII.  The AT domain is fully loaded with MM, whereas the ACP active 
site peptide was found both in holo and MM-loaded states.    
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Figure 3.8. Cryo-EM and reconstructed X-ray crystallography/NMR images of MM-loaded 
PikAIII.  Here, a single conformer exists, with the MM-loaded ACP between the AT and KS 
domains.  Data generated by S. Dutta. 
 
3.3.5 Pentaketide-loaded PikAIII structure determination and LC/FT-ICR MS confirmation 
 In the assembly line-like pikromycin biosynthetic process, there are two potential first 
steps: loading of the MM extender unit, as described above, or loading of the upstream 
intermediate, in this case, a pentaketide.  When thiophenol-pentaketide was incubated with 
holo PikAIII, the overall structure showed multiple conformational changes as compared to holo 
PikAIII (Figure 3.9).  The AT domains lean in toward the KS domains, partially blocking the KS 
active site.  This adjustment may be necessary to protect the labile pentaketide until the MM 
extender unit is added.  A more dramatic structural change is the end-to-end flip of the KR 
domains.  As a result of this flip, the KR active sites become closer to the AT domain active sites.  
Mutagenesis showed that the proximity of the active sites is important to catalytic function.  
These data additionally demonstrate that the position and orientation of the KR domains are 
dependent on the other domains and reveal evidence of interdomain cross-talk.  The mass 
spectrometry data confirmed that the KS domain was loaded with pentaketide (Figure. 3.10).  
Previous LC/FT-ICR MS work carried out with the PikA system was unable to detect any 
substrate bound to the pentaketide54, therefore, these mass spectrometry data were 
particularly exciting and insightful42.  Successful detection of pentaketide-loaded KS was very 
likely due to the LC/FT-ICR MS protocol changes and improvements.   
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Figure 3.9. Cryo-EM and X-ray crystallography/NMR reconstructions of pentaketide-loaded holo 
PikAIII.  The ACP shifts down and exists as a single conformer, compared with holo PikAIII.  The 
most dramatic change is displayed in the two right-most panels, an end-to-end flip of the KR 
domain.  Data generated by S. Dutta. 
 
 
Figure 3.10. Partial mass spectra of KS active-site peptides from LC/FT-ICR MS of trypsin 
digested pentaketide-loaded PikAIII.  Although only partial loading of the KS active site was 
observed, for the first time, there is mass spectral evidence of pentaketide loading on the KS.  
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3.3.6 MM- and pentaketide-loaded PikAIII structure determination and LC/FT-ICR MS 
confirmation 
 The condensation of MM and the pentaketide intermediate from PikAII forms a β-
ketohexaketide, the first intermediate in PikAIII catalysis.  The overall structure of MM and 
pentaketide-loaded PikAIII (Figure 3.11) is very similar to the architecture of the pentaketide 
loaded structure (Fig. 3.9).  The AT domains are shifted even further toward the KS, blocking the 
side entrance to the KS active site.  This shift likely prevents the immediate transfer of the 
pentaketide from ACP4 to the KS active site.  Although the ACP is in the same overall position, 
its active site points toward the NADPH binding site in the KR domain, which is involved in the 
subsequent catalytic step (discussed below).  LC/FT-ICR MS was able to determine each 
domain’s active site peptides and bound substrates/products (Figure 3.12).  The KS was partially 
loaded with pentaketide, the AT was fully loaded with MM, and the ACP showed evidence of 
both MM and β-ketohexaketide product bound to the Ppant arm.  Although each active site 
peptide was of low abundance, rendering tandem mass spectrometry a significant challenge, 
the nearly perfect mass accuracy confidently confirmed the identity of each peptide, substrate, 
and product. 
 
Figure 3.11. Cryo-EM and X-ray crystallography/NMR reconstructions of MM- and pentaketide-
loaded PikAIII, yielding β-ketohexaketide product on the ACP.  The overall architecture is similar 
to pentaketide-loaded PikAIII, except for the AT domains shifting toward the KS domain more 
dramatically, as demonstrated in the cartoon.  Data generated by S. Dutta and J. Whicher. 
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 Figure 3.12. Partial mass spectra of active-site PikAIII peptides from LC/FT-ICR MS of trypsin 
digested MM- and pentaketide-loaded PikAIII.  Pentaketide was detected on the KS, MM was 
detected on the AT, and both β-ketohexaketide product and MM were detected on the holo 
ACP.  
 
3.3.7 MM- and pentaketide-loaded PikAIII structure determination and LC/FT-ICR MS 
confirmation in the presence of NADPH 
 
 The final PikAIII catalytic step is β-ketohexaketide reduction by the KR domain, resulting 
in a mass shift of 2 Da to yield β-hydroxyhexaketide.  This reaction requires NADPH to power 
the KR.  An initial experiment with 4 mM NADPH did not result in LC/FT-ICR MS detection of β-
hydroxyhexaketide.  However, both 16 mM of NADPH and 4 mM of NADPH buffered in HEPES 
yielded the expected reduction.  High resolution mass spectrometry was vital for this part of 
the experiment, because the detected peptides had a 2+ charge, resulting in an m/z change of 
only 1.  Moreover, there was a mixture of β -ketohexaketide, and β –hydroxyhexaketide, 
resulting in a broad isotopic pattern (Figure 3.13).  Based on the isotope pattern, it appears that 
two ketones were reduced, entirely possible due to the excess NADPH added. 
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 Figure 3.13. Partial mass spectra of the ACP5 active-site peptide from LC/FT-ICR MS of trypsin 
digested MM- and pentaketide-loaded PikAIII in the absence (top) and presence (bottom) of 
NADPH.  Calculated isotope patterns are shown on the right for β-ketohexaketide and β-
hydroxyhexaketide, respectively, bound to the active site peptide.  The bottom mass spectrum 
shows evidence of a mixture of these two hexaketides.  The purple triangles indicate the 
expected abundancies of the two first isotopic peaks of the β-ketohexaketide and match well 
with the experimental data.  The pink squares indicate the expected isotopic abundancies for a 
1:1 mixture of β-ketohexaketide and β-hydroxyhexaketide.  The poorer fit at higher m/z ratios 
indicate that a second reduction may have occurred due to excess NADPH.  
 
 In the presence of NADPH, the overall structure of MM- and pentaketide-loaded PikAIII 
is similar to the structure in the absence of NADPH, with the AT domains leaning in toward the 
KS domain and the KR domain’s active site directed toward the AT.  However, three different 
conformers were observed, each with the ACP located outside of the catalytic chamber, under 
the KR domains (Figure 3.14).  Although there are three different positions, the ACP has little 
flexibility under these conditions.  The ACP active site is directed away from PikAIII and is 
prepared to transfer the substrate to the next module, PikAIV.   
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Figure 3.14. Cryo-EM and X-ray crystallography/NMR reconstructions of β-hydroxyhexaketide-
bound PikAIII.  Although there are three different conformers, the ACP (in fuchsia, yellow, and 
cyan) has limited flexibility.  The ACP is positioned to transfer its substrate to the next module.  
Data generated by S. Dutta. 
 
3.4 Conclusions 
 This work presents the first structure of an entire type I PKS module and captures the 
movement of an ACP, for which the location depends on the bound substrate on the Ppant arm 
(Figure 3.15).  The cryo-EM structures show the overall structure of PikAIII during each step of 
the assembly line-like process whereas LC/FT-ICR MS determines and confirms each domain’s 
active site occupancy.  The MS data were consistently in agreement with the cryo-EM data and 
provide powerful evidence to support the unexpected cryo-EM structures.  The ACP does not 
appear to engage in protein-protein interactions with other domains unless the appropriate 
substrate is loaded. 
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Figure 3.15. An overall summary of the ACP (in orange) movement depending on the substrate 
bound to it via Ppant.  The figure also demonstrates the KR end-to-end flip.  Figure produced by 
J. Whicher. 
Moreover, there is evidence of interdomain cross-talk in the PikAIII module.  For example, the 
end-to-end flip of the KR domain positions the KR active site near other active sites and the AT 
movements that block the KS active site entrance only occur when a pentaketide or hexaketide 
intermediate is present.  These changes provide insight into understanding the kinetics of the 
module and appear to position each domain in anticipation of the next step in the process.  
These findings provide the first plausible mechanism, not only for ACP transfer, but also a 
detailed look into how type I PKSs function and produce natural products.  This discovery will 
provide improvements in developing more effective combinatorial biosynthesis approaches and 
will allow for improved and more insightful synthesis using unnatural substrates.   
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Chapter 4 
Elucidation of the Curacin and Jamaicamide Biosynthetic 
Pathways Via Phosphopantetheine Ejection 
 
4.1 Introduction 
A large number of antibiotics, anti-cancer agents, immunosuppressants as well as other 
drugs originate from nature1-5.  Many of these natural products are synthesized by protein 
complexes called polyketide synthases (PKSs), non-ribosomal peptide synthetases (NRPSs) or 
hybrids of the two6-11.  Type I PKS biosynthetic pathways consist of multiple protein modules, 
each containing multiple domains, and act as an assembly line operating sequentially.  Type I 
PKS modules minimally consists of three domains: a ketosynthase (KS), an acyl transferase (AT), 
and an acyl carrier protein (ACP)6.  The KS domain is responsible for catalyzing carbon-carbon 
bond formations via a Claisen condensation, elongating the natural product intermediate by a 
two or three carbon chain6,12.  The AT chooses an extender unit and transfers it to the ACP6.  
The ACP tethers and transfers natural product intermediates via a thiol residue on a 
phosphopantetheine (Ppant) post-translational modification6,13,14.  Other domains add 
structural diversity to the natural product and include ketoreductases (KRs), dehydratases 
(DHs), and enoyl reductases (ERs), which generate -hydroxyl, enoyl, or fully saturated 
products, respectively15.  Mixing and matching these domains results in a large number of 
pathways that create very diverse natural products.   
Moorea producens (formerly Lyngbya majuscula16) is a marine blue-green algae, a 
cyanobacterium which contains multiple biosynthetic pathways, generate interesting products, 
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such as the barbamides, jamaicamides, and curacin A17,18.  Most cyanobacterial natural 
products, including those that originate from Moorea producens, are PK-NRP hybrids19.  The 
barmamides have molluscicidal activity and have unusual chemical groups including a 
trichloromethyl group, a methyl enol ether, a thiazole ring, and E-alkene formation19-21.  The 
jamaicamides, aptly named as they were first isolated in Hector’s Bay, Jamaica, block sodium 
channels, are toxic to fish, and have unique functional groups such as an alkynyl bromide, a 
vinyl chloride, and a pyrrolinone ring17,22.  Curacin A is an anti-cancer agent which inhibits 
tumor cell growth and contains interesting chemical features, such as a cyclopropane, a 
thiazoline, a cis-double bond, and a terminal alkene23,24.  Both the Cur and Jam biosynthetic 
gene clusters, responsible for producing Curacin A, and the jamaicamides, respectively, have 
high sequence identity in their early segments and include a 3-hydroxy-3-methylglutaryl (HMG)-
CoA synthase-like (HCS) gene cassette encoding enzymes to create a -branch in the polyketide 
intermediate25,26.  The sections with high sequence identity in the Cur and Jam gene clusters 
encode for an Fe2+/α-ketoglutarate (α-KG)-dependent halogenase (Hal) and three ACPs in the 
CurA and JamE modules17,24,27.  The halogenase in the Jam pathway is unsurprising because 
there is a vinyl chloride in the final natural product and halogenation is well characterized in 
biosynthetic pathways28,29.  However, Curacin A lacks a halogen, so the halogenase’s function 
was less certain although it had been speculated to aid in cyclopropane formation30.  Additional 
domains that exhibit high sequence identity are an HMG-ACP synthase in CurD and JamH, a 
dehydratase (ECH1) in CurE and JamI, a decarboxylase (ECH2) domain in CurF and JamJ, and an 
enoyl reductase (ER) domain in CurF and JamJ17,24,25,31.  Generally, sequence identity over fifty 
percent results in the same structure and therefore function, however, the biosynthetic 
products from the Cur and Jam ER domains were found to be quite different: a cyclopropane 
for the Cur ER and a vinyl chloride for the Jam ER31-33.  Previous collaborations between the 
Hakansson lab and the Smith, Gerwick, and Sherman labs have characterized these enzymes 
and their reaction order structurally and biochemically, revealing insight into the catalytic 
mechanism of each pathway25,31,34.   
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Figure 4.1. Divergence in the curacin and jamaicamaide biosynthetic pathways.  The pathways 
diverge at the ECH2 step, in which the CurF ECH2 creates an α-β double bond, whereas, the Jam 
ECH2 forms a β-γ double bond.  JamJ ER is unreactive toward the JamJ ECH2 product, yet reacts 
with the CurF ECH2 product.  Figure generated by Khare, D. 
For example, it was found that, in the curacin pathway, CurA Hal chlorinates the HMG-ACP, 
followed by dehydration and decarboxylation by ECH1 and ECH2, respectively35.  The 
jamaicamide pathway is identical through the dehydration step, but diverges at the ECH2 step.  
Here, CurF ECH2 forms an α,β-enoyl-γ-chloro-ACP whereas the 59% identical JamJ ECH2 forms a 
β,γ-enoyl-γ-chloro-ACP31,36.  The next domain, the ER, produces stark differences.  Addition of 
CurF ER results in the formation of a cyclopropane, involving hydride addition from NADPH and 
chloride elimination, whereas the 65% identical JamJ ER has no function: it does not react with 
the β,γ-enoyl-γ-chloro-ACP product from the JamJ ECH2 (Figure 4.1).  However, JamJ ER reacts 
with the α,β-enoyl-γ-chloro-ACP product of CurF ECH2, resulting in the reduction of an α-β 
double bond31 (Figure 4.2).  These two pathways are an example of how combinatorial 
biosynthesis, even with a single enzyme, may lead to different functional groups. 
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 Due to the major functional differences in the ER domains between the Cur and Jam 
pathways, it is of interest to structurally investigate ER domains for potential differences that 
could explain the formation of different functional groups.  Generally, an ER domain’s function 
is to reduce an α-β alkene to an alkane6.  This function is found in multiple ERs in the Cur and 
Jam pathways, including CurH ER, CurK ER, a second ER domain within JamJ, and JamL ER.  The 
Cur and Jam ER domains belong to a superfamily of medium chain dehydrogenase/reductase 
(MDR) proteins that are well studied and include Zn2+-dependent alcohol dehydrogenases and 
quinone oxidoreductases37-39.  A common theory regarding the mechanism of the MDR and PKS 
ER reductions involves a hydride transfer from the NADPH nicotinamide to the -carbon atom 
of the unsaturated substrate to form an enolate intermediate, followed by proton transfer from 
the enzyme to generate a saturated product39.  The assumed mechanism for the CurF ER 
cyclopropanase includes similar initial steps of hydride transfer and formation of an enolate 
intermediate, however, chloride removal and a simultaneous nucleophilic attack of the -
carbon on the -carbon result in the formation of a cyclopropane30. 
 
Figure 4.2. In a PKS enoyl reduction reaction the expected first step involves a hydride transfer 
from the cofactor NADPH to the unsaturated substrate, followed by protonation at the α-
carbon atom (left).  The unique CurF ER catalyzes the nucleophilic displacement of the chlorine 
atom in an NADPH-dependent manner to form the highly strained cyclopropane ring31 (right). 
Figure generated by Khare, D. 
 
Although some mechanistic details regarding PKS ERs have been deduced, the overall molecular 
and structural bases for enoyl reduction are unknown.  Structural and biochemical 
investigations to determine a potential proton donor for reduction have been unsuccessful.  For 
example, site-directed mutagenesis based on a homology model for the erythromycin ER 
identified conserved amino acids for controlling ER stereochemistry, but was unable to identify 
a proton donor40,41.  Crystal structures of other PKS ERs, including a KR-ER didomain from 
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spinosyn (Spn) and a trans-acting ER from lovastatin, did not reveal a proton donor either42,43.  
To understand the structural and molecular basis of the unusual CurF ER cyclopropanase, a 
combination of X-ray crystallography and a phosphopantetheine ejection assay via FT-ICR mass 
spectrometry was employed.   
4.2 Experimental 
4.2.1 Cloning, expression and protein purification 
Proteins were expressed by D. Khare as follows: CurF ER (amino acids 275-611, here numbered 
1-337) and the first ER domain within JamJ (amino acids 260-594, here numbered 1-335) were 
amplified by PCR from plasmids encoding CurF ER and JamJ ER31.  The amplified products were 
inserted into pMCSG7 (JamJ ER) and pMocr (JamJ ER and CurF ER) vectors and expressed in E. 
coli BL21 (DE3) cells44,45.  Cells were grown to an OD600 of 1.0 at 37°C in TB supplemented with 
4% glycerol, incubated at 20°C for 1 hr, induced with 0.4 mM IPTG, and grown for an additional 
20 hr.  The cell pellet from a 0.5-L culture was resuspended in 40 mL Buffer A (100 mM Tris pH 
7.8, 500 mM NaCl, 5 mM imidazole and 10% glycerol) and lysed by ultrasonication. All 
purification steps were carried out at 4°C.  The soluble fraction was loaded to a HisTrap Ni2+ NTA 
column (GE Healthcare), washed with Buffer A and eluted with a linear gradient of 5-500 mM 
imidazole.  The His6-Mocr tag was cleaved by TEV protease and the tag-free ER purified on a 
Ni2+ NTA column.  Further purification was done on a Superdex 200 size exclusion column 
equilibrated with Buffer B (10 mM Tris pH 7.8, 50 mM NaCl and 10% glycerol).  Selenomethionyl 
labeled JamJ ER was purified similarly to the wild type protein, except that the pMocr::JamJ ER 
plasmid was transformed into the E. coli met- auxotroph strain B834 (DE3), cells were grown in 
minimal media (Molecular Dimensions), and 1 mM DTT was added in all subsequent purification 
steps.  All excised PKS ER domains eluted with an apparent molecular weight of 40 kDa, 
corresponding to a monomer.  A JamJ-CurF ER chimera was generated by using overlap PCR to 
swap 12 amino acids of JamJ ER with the corresponding 14 amino acids from CurF ER.  Mutants 
of JamJ and CurF ER in the pMocr vector were generated by site-directed mutagenesis and 
purified as described above.   
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4.2.2 Crystallization, data collection, structure determination and refinement 
Details of these steps are provided by D. Khare in the manuscript associated with this chapter46. 
4.2.3 ACP linked substrate and ER activity assay 
The following experiments were performed by D. Khare: The ACP-linked HMG substrate was 
generated and ER was assayed as described previously31.  Briefly, 100 μM of ACP-linked 
substrate was incubated with 10 μM enzymes (CurA halogenase + CurE ECH1 + CurF ECH2) and 
the corresponding cofactors at 25°C for 25 min each.  The reactions were initiated by exposing 
the reaction mixture to O2.  The γ-Cl-3-methylcrotonyl-ACP sample was further treated with 
CurF ER (100 nM) or JamJ ER (100 nM) for 5 min at 25°C.  The reactions were quenched by 
addition of 10% formic acid (CH2O2) and the ACP-loaded sample was separated from the 
reaction mix by reverse phase HPLC using a Source 15RPC ST4.6/100 column (GE Healthcare).  
The proteins were eluted with a linear gradient from 30% to 70% of CH3CN (0.05% CF3COOH 
and 0.05% CH2O2)/H2O (0.05% CF3COOH and 0.05% CH2O2).   
 
4.2.4 ACP sample analysis by FT-ICR mass spectrometry 
HPLC fractions were diluted at a 40:100 ratio in 50/50 HPLC-grade H2O (ThermoFisher 
Scientific) and CH3CN (ThermoFisher Scientific) with 0.1% CH2O2 (ThermoFisher Scientific).  
Samples were directly infused into the electrospray source of an actively shielded 7T SolariX 
quadrupole FTICR-MS (Bruker Daltonics).  Data were gathered from m/z 200-2000 in positive 
ion mode.  Electrospray was conducted at 4,500V with 128 scans per spectrum and the 
transient set to 1M data points.  External ion accumulation in a hexapole was 0.5 s with one ICR 
fill prior to excitation and detection.  External calibration utilized HP-mix (Agilent) mixed with 
ubiquitin (Sigma Aldrich).  Collision-induced dissociation (CID) was performed in the collision 
cell hexapole with ultra-high purity argon (Cryogenic Gases) at 10 V and all charge states 
present were fragmented.  Quantification of the Ppant arm and attached products was carried 
out as previously described35,47.  
4.3 Results and Discussion 
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4.3.1 Enoyl Reductase Concentration Optimization and Utilization of Isotopic Fine Structure 
 The concentration of the ER incubated with the ACP had a large effect on the generated 
natural product intermediate.  100 nM of JamJ ER wildtype completely reduced the vinyl 
chloride, whereas 1 nM or 10 nM partially reduced the vinyl chloride (Figure 4.3).  Due to the 
mass difference of 2 Da before and after the vinyl chloride reduction, ultra-high resolution mass 
spectrometry was imperative to determine the concentration effects.  Differences of 1 or 2 Da 
are easily detectable for both the intact protein and the fragmentation products after CID.  10 
nM and 100 nM were selected as suitable ER concentrations to determine the effects of the 
point mutations. 
 
Figure 4.3. The concentration of JamJ ER has a significant effect on the ACP-bound reaction 
product.  0 nM, 10 nM, and 100 nM has no effect, partially reduces a vinyl chloride, and 
completely reduces a vinyl chloride, as shown by the measured molecular weight of the intact 
ACP.   
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A similar concentration dependence was observed for the CurF ER (Figure 4.4).  The 
concentrations of CurF ER ranged from 1 fM to 1000 nM.  Suitable concentrations ranged from 
0.1 nM to 100 nM for determining CurF ER effects on the cyclopropane formation.  Although 
the cyclopropane formation has a larger mass shift than the reduction of the vinyl chloride, 
ultra-high resolution mass spectrometry remains an ideal and precise method to determine the 
effects of the enzyme’s concentration. 
 Ultra-high resolution mass spectrometry was also necessary for relative quantitation, 
conducted by measuring and normalizing peak heights.  For the JamJ ER, resulting in a mass 
difference of 2 Da, the third isotopic peak of the halogenated, dehydrated, and decarboxylated 
product is less than half a milliDalton from the monoisotopic peak of the reduced product.  
Also, due to the chlorine atom in both substrate and product, their isotopic patterns are 
atypical, with the third isotopic peak being more abundant than the second isotopic peak due 
to the presence of 37Cl (Figure 4.5).  
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Figure 4.4. Cyclopropane formation efficiency is dependent on the concentration of the CurF ER 
enzyme.  0.01 nM and 1 nM partially convert the natural product intermediate, whereas 100 
nM mostly converts the intermediate.   
 
Figure 4.5. Resolved isotopic fine structure for a mixture of non-reduced substrate and reduced 
product.  The left peak corresponds to the 37Cl isotope of the non-reduced substrate and the 
right peak corresponds to the monoisotopic peak of the reduced product. 
4.3.2 JamJ ER crystal structure and mechanism determination with FT-ICR mass spectrometry 
 The crystal structure for JamJ ER was solved.  X-ray crystallography revealed the 
structure of JamJ ER with its bound cofactor at 2.25 Å and in the apo form at 1.8 Å.  Its structure 
has the typical fold of the MDR enzyme superfamily to which it belongs48,49.  MDR superfamily 
members predominantly exist as dimers or tetramers.  However, the oligomeric state of PKS ER 
enzymes is unique as the JamJ ER is a monomer42,43.  Like other PKS ERs, the NADPH cofactor 
binds to JamJ ER in a narrow cleft between the catalytic and nucleotide-binding domains 
through hydrogen bonds and van der Waals interactions42,43.  
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 Figure 4.6. Ribbon diagram 
of a JamJ ER monomer (left). The putative catalytic domain is colored in blue and the NADPH 
binding domain is in yellow.  The two domains are connected by helices α3 and α9- α10 (light 
purple).  Cofactor NADPH is colored in red, blue, and orange.  Ball and stick model (right) with a 
stereoview of the representative electron density around the cofactor NADPH shown from a Fo-
Fc map (light green mesh) at 2.25 Å resolution.  Hydrogen bonds between the cofactor NADPH 
and JamJ ER are illustrated as black dashed lines.  Data generated by Khare, D. 
The nicotinamide group from NADPH is at an open end of the active site cleft, defining the 
substrate entrance.  D275 is at the entrance to the substrate channel, and in both structures is 
within reach of a conserved basic side chain (CurF R253, JamJ K251).  K251 has been proposed 
as the proton donor in JamJ ER reduction, however mutagenesis coupled with FT-ICR mass 
spectrometry refutes this proposal, as shown in Figure 4.7.  When this residue is substituted for 
an alanine or an arginine, reduction activity is retained.   
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Figure 4.7. Intact 12+ charge state and Ppant ejection products for JamJ HMG-ACP following 
incubation with halogenase (Hal), dehydratase (ECH1), and decarboxylase (ECH2) (top) as well as 
additional incubation with K251A JamJ ER at 10 nM (middle) and 100 nM (bottom). No effect is 
seen from this mutation as reduction still occurs. 
 
The phosphopantetheine assay determined and quantified the amount of reduction generated 
by the JamJ ER.  High resolution ( 70,000) was necessary to detect and identify reduced 
product: the action of JamJ ER results in the addition of two hydrogens, a mass difference of 2 
Da for the intact protein.  If a mixture of reduced and non-reduced protein is present, the 
apparent mass difference is less than 2 Da.  High resolution confirms the tandem mass 
spectrometry (MS/MS) ejected substrate and product, respectively: isotopic fine structure is 
observed due to the presence of chlorine in both the substrate and product.  As observed by 
FT-ICR mass spectrometry, the K251A mutation has no effect (Fig. 4.7).  A PKS ER active site 
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should bind its substrate near the NADPH hydride donor and near a proton donor.  It should 
also provide stabilizing hydrogen bonds to the enolate intermediate that forms following 
hydride transfer.  Although the function is known, the identity of the amino acids that fulfill this 
role in PKS ERs and other members of the MDR superfamily are wholly unknown, including the 
proton donor in JamJ ER.  Although D273 mutated to an alanine inhibited reduction (Figure 4.8), 
it did not eliminate it completely.  No single amino acid was found to be essential for vinyl 
chloride reduction; therefore, it is possible that the proton donor is a water molecule40,43.   
 
Figure 4.8. A summary of percent reduction for the three forms of JamJ ER investigated.  The 
left bars for each form (maroon) represent the non-reduced substrate (m/z 377) and the right 
bars (purple) represent the reduced product intermediate at m/z 379. 
 
4.3.3. CurF ER crystal structure and mechanism determination with FT-ICR mass spectrometry 
The crystal structure of CurF ER was also solved, revealing the structure of CurF ER with 
its bound cofactor at 0.96 Å; overall its structure is very comparable to the JamJ ER domains, 
with a Cα core rmsd of 0.7 Å for JamJ ER-NADPH and 0.8 Å for JamJ apo-ER. Overall, the NADPH 
cofactor binds in a similar way to CurF ER.  In addition, the NADPH nicotinamide position is 
stabilized by hydrogen bonds between the amide and the ER backbone at D275, the carbonyl of 
F274, and NH of M276.  
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Figure 4.9. Ribbon diagram of CurF ER monomer in rainbow colors (left).  Cofactor NADPH is 
colored in red, blue, and orange.  Ball and stick model (right) with stereoview of the 
environment around the cofactor NADPH at 0.96 Å resolution in blue.  Hydrogen bonds 
between the cofactor NADPH and CurF ER are indicated as black dashed lines.  Data generated 
by Khare, D. 
 
The proximity of the conserved and oppositely charged side chains of D275 and R253 may be 
critical to an ER conformation that exists only when the substrates are bound; both amino acids 
have been proposed as the proton donor in ER reduction40,42.  The phosphopantetheine assay 
determined and quantified the amounts of natural product intermediates generated by the 
CurF ER.  These sites as well as other amino acids in or near the active site were mutated to 
determine a proton donor.  Interestingly, substitution of CurF ER R253 with the more typical 
lysine residue reduced cyclopropanation the most (Figure 4.10).  The D275 mutation reduced 
cyclopropanation moderately.  When Y58 and Y108 were mutated to alanine residues, 
cyclopropanation was also reduced.  CurF R46 is another conserved basic residue near the 
substrate entrance that interacts with D275, but had a modest reduction in cyclopropanation 
when mutated to an alanine.  The S277 is further away from the active site and mutated to 
alanine as a control.  Predictably, this mutation had no effect on the cyclopropanation activity.  
Like JamJ ER, no single amino acid in the CurF ER was essential for cyclopropane formation, 
providing further evidence for a universal proton donor, such as a water molecule. 
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Figure 4.10. A summary of cyclopropane formation efficiency for the CurF ER mutants 
investigated.  The left bars for each form in green represent the cyclopropane product (m/z 343) 
and the right bars in blue represent the non-reduced substrate at m/z 377. 
 
In many ways, JamJ ER and CurF ER are comparable with other ERs in this family; they 
both have similar topology to the MDR superfamily and do not have a single amino acid 
essential for catalytic activity, whether it performs a reduction or forms a cyclopropane.  
Therefore, the proton donor for both ERs is likely to be a water molecule as hypothesized by 
others40,43.  Notably, the CurF ER structure also reveals that the size of the substrate binding 
pocket correlates with the size of the substrate acyl group.  The binding pocket extends into the 
hydrophobic core of the substrate-binding domain, indicating that the pocket size could be 
important for substrate selectivity.  Overall, the active site and substrate cleft have conserved 
amino acids, except for a substrate loop which lines the substrate cleft, facing the nicotinamide 
ring and may be used for substrate recognition and selectivity.  In JamJ and CurF, it is a longer 
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loop and also differently structured from similar ERs such as Spn ER.  The JamJ and CurF ER 
sequences vary the most amongst this loop region as well, as seen in Table 4.1. 
 
Table 4.1. Sequences of various enoyl reductases, highlighting the varying loop regions.  
Table generated by Khare, D. 
 
4.3.4 JamJ-CurF ER chimera formation and catalytic activity determination with FT-ICR mass 
spectrometry 
 Although the JamJ and CurF ER structures have a high degree of similarity, with 65% 
identity, they differ mostly in the substrate loop area and generate products with very different 
properties and functions.  Two questions beg to be answered: are the differences in the 
substrate loop responsible for the differences in function for the two ERs and can the JamJ ER 
be mutated and manipulated into a cyclopropanase, similar to the CurF ER?  Due to the 
difference in both amino acids and length in the loop, a chimera ER was designed with CurF 
amino acids 54-68 dubbed as the “cyclopropanase loop.”  Overall, as observed in the CurF ER 
crystal structure, the cyclopropanase loop is very ordered, despite the lack of alpha helices and 
beta sheets, with at least 15 hydrogen bonds for support.  Another reason for selecting this 
group of amino acids was R62, which is only found in the CurF ER and is important for the highly 
structured loop.  From the CurF ER crystallography data, it was determined that R62 forms four 
hydrogen bonds from its sidechain to uncharged carbonyl oxygen atoms and a fifth hydrogen 
bond with a water molecule in close proximity to the chlorine atom in the CurF substrate.  This 
residue is also within 9 Å of the nicotinamide group and is ideally positioned to stabilize a 
chloride leaving group near the bound water.  The function of the cyclopropanase loop was 
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tested by transplanting the loop into JamJ ER K251R, creating an active and stable enzyme.  
Additional substitutions were performed near the loop, however, these changes led to an 
unstable protein.  With the natural CurF ER substrate, 3-chloromethyl-crotonyl-ACP, both the 
reduced product and cyclopropane product were detected with FT-ICR MS, although the 
cyclopropane was only about 10% of the total product (Figure 4.11).  This chimera protein 
demonstrates the ability to form a cyclopropane and provides evidence that the 
cyclopropanase loop determines the unique activity of the curacin biosynthetic pathway.  
Another outcome to note is that although the substrate loop is a large contributing factor to 
forming the cyclopropane in the CurF ER, it is not a large contributing factor to reductase 
activity in the JamJ ER, as the chimera demonstrates both activities.   
 
Figure 4.11. Partial mass spectra from Ppant ejection of the ACP-bound products following 
incubation of γ-Cl-3-methylcrotonyl-ACP with the JamJ-CurF ER chimera (top).  The observed 
products constitute a mixture of the products following incubation with JamJ ER and Cur F ER, 
respectively.  ACP-bound products were ejected by CID and detected and quantified by FT-ICR 
MS.  The cyclopropane product intermediate is at m/z 343, the non-reduced substrate 
intermediate is at m/z 377, and the reduced product intermediate is at m/z 379.  Bar graphs 
(bottom) display activity of the wildtype and chimera ERs as normalized percent formation of 
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the cyclopropane (in green), unreacted (in maroon and light blue), and the reduced product (in 
purple) at different ER concentrations. 
4.4 Conclusions 
 Overall, this study sought to determine the structural and mechanistic differences 
between two enoyl reductase domains with high identity but dramatically disparate properties.  
JamJ ER applied to an HMG-ACP, also incubated with halogenase, dehydratase, and 
decarboxylase, results in the expected reduction of an α-β alkene, whereas CurF ER results in 
the formation of a cyclopropane in the natural product intermediate covalently bound to the 
ACP.  Although the two biosynthetic pathways have high identity and therefore theoretically 
similar functions, the jamaicamide pathway generates products known as the jamaicamides, 
toxic to fish and blocking sodium channels, while the curacin pathway produces Curacin A, an 
anti-cancer agent.  The crystal structures for the CurF ER and JamJ ER were solved.  Based on 
the crystal structures, point mutations were made near the active site in each ER to determine 
which amino acids were essential for catalytic activity.  Neither ER had a single amino acid 
responsible for catalytic activity.  However, D273 in Jam and R253, Y58, and Y103 in Cur, 
contributed more to activity, as reduction or cyclopropane formation decreased when these 
amino acids were mutated to alanine residues.  Crystallography showed major differences 
between JamJ ER and CurF ER in the substrate-binding region, which led to the design of a 
‘chimeric’ ER enzyme, which generates both reduced product and cyclopropane.  The amino 
acids from the CurF ER substrate loop were transplanted into the JamJ ER K251R enzyme to 
create this chimeric protein. This novel enzyme demonstrated that the substrate loop is 
important, though not fully responsible for ER action, as reduction still occurred with the 
substitution.  The insights into the structure and function of the CurF ER and the JamJ ER, 
gained by high resolution mass spectrometry and X-ray crystallography, provide important 
details into the inner workings of the enzymes, including the potential for transforming a toxic 
product into an anti-cancer drug. 
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Chapter 5 
Phosphopantetheine IR Absorptivity for Data Independent 
Selective Identification of Natural Product Biosynthetic 
Pathways 
 
5.1 Introduction 
Bottom-up or shotgun proteomics has transformed into a widespread practice, in which 
identifying and quantifying proteins and peptides has become routine1-3.  Most proteomics 
approaches involve a data-dependent liquid chromatography tandem mass spectrometry 
(LC/MS/MS) procedure, in which peptides from proteolytic digestion of the protein sample are 
selected for fragmentation in order of abundance as they elute from the LC column(s).  Modern 
mass spectrometers typically acquire one precursor ion mass spectrum followed by 5-10 
peptide MS/MS spectra.  In order to avoid fragmenting the same peptides multiple times, 
dynamic exclusion is employed in which an m/z ratio chosen for fragmentation populates an 
exclusion list for a set period of time.  For complex samples such as whole cell proteomes, these 
procedures may include additional upstream clean-up or enrichment steps prior to LC/MS/MS4-
6.  Although shotgun proteomics has demonstrated its success, this method cannot completely 
map a proteome; rather, it can only identify the most abundant peptides in a complex mixture.  
One study demonstrated that approximately 100,000 peptides elute in a traditional bottom-up 
LC/MS/MS run, but only about 16% of these peptides are detected and analyzed7.  Evolving 
instrumentation improvements, including sensitivity increases, are not yet powerful enough to 
sequence each peptide in a complex mixture8,9.  Fourier transform (FT) mass spectrometers are 
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particularly vulnerable to this shortcoming of data-dependent analysis, as their trademark ultra-
high resolution is directly proportional to the length of the time domain signal, thus, in order to 
maintain performance, they have lower throughput compared to other mass 
spectrometers10,11.  One strategy for circumventing issues associated with data dependent 
acquisition (DDA) is to increase the dynamic range of the sample, primarily accomplished with 
fractionation or enrichment8,12.  Examples of such strategies include subcellular fractionation, 
affinity enrichment, 2D gel electrophoresis, isoelectric focusing and cation or anion exchange 
methods such as MudPIT13-17.   
Many labs have recognized the shortcomings of data-dependent analysis and have 
developed alternative approaches, including elimination of MS/MS, or data independent 
LC/MS/MS methods (Table 5.1).  Data independent acquisition (DIA) procedures produce 
product ion spectra without first selecting a precursor ion, i.e., all co-eluting peptides are 
fragmented together12.  The accurate mass and corresponding retention time (AMRT) method 
was developed for quantitative label-free proteomics18 and is similar to the accurate mass and 
time (AMT) tag concept that compares accurate masses and their corresponding LC elution 
times to a custom database19.  This latest iteration of the AMT tag approach is an improvement 
of a previous AMT tag strategy that only utilized accurate mass.  In this former implementation, 
“AMT” was an abbreviation for “accurate mass tag”20.  The improved AMT tags are unique to 
mass spectral peaks 88% of the time and can identify thousands of peaks in a single LC/MS 
run19.  Although the AMT tag is best suited to an FT mass spectrometer to ensure high mass 
accuracy, it is also amenable to time-of-flight instruments19.  The main disadvantage of the AMT 
tag approach is the requirement for a custom database.   
The precursor acquisition independent from ion count (PAcIFIC) DIA method increases 
dynamic range of complex samples by repeatedly analyzing a sample via multiple LC/MS/MS 
runs at specific but different m/z ranges, simultaneously fragmenting all precursor ions within 
the set range, typically a few Daltons21.  Product ions can be observed even when a precursor 
ion was not detected.  With this setup, PAcIFIC has been shown to identify over 2,000 proteins 
and up to 13,000 unique peptides from a whole cell lysate.  Although the numbers of 
identifications are unprecedented, the data collection time is about five days21.  The time 
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consuming data acquisition in PAcIFIC is an obvious flaw that was later addressed by utilizing 
higher throughput instruments to expedite the process, shortening the acquisition time to two 
or three days11.  Another PAcIFIC flaw was the lack of quantitative data, which was addressed 
by including isobaric tagging11.  Although the data collection duration is still very long, PAcIFIC 
can detect proteins across the entire measurable dynamic range.   
Another LC/MS/MS DIA approach is the MSE method, introduced by Waters for their 
ultrahigh pressure LC (UPLC)/Synapt ion mobility-quadrupole time-of-flight (TOF) instruments.  
In this technique, the collision cell rapidly switches between low and high collision energies, 
producing alternating precursor and fragment ion spectra, both with high mass accuracy22.  The 
duty cycle is very high, ensuring that both MS and MS/MS data are obtained for each narrow 
peak in the UPLC chromatogram.  There is no quadrupole isolation; however low collision 
energy precursor ion spectra are matched with their associated high collision energy product 
ion spectra through sophisticated computer algorithms based on accurate retention time.  Gas-
phase ion mobility separation can be employed to further separate co-eluting peptides.  This 
method has successfully been applied to phosphopeptides, which are generally dynamic and of 
low abundance23.  MSE is an accurate method and has been utilized for comparing the 
reproducibility of two enrichment workflows for low abundance proteins24.  The main 
disadvantage of MSE is that it is only available on a single commercial platform.  The “all ion 
Fragmentation” (AIF) technique, designed for Orbitrap instruments, is similar to MSE.  In this 
method, an MS scan is first analyzed in the orbitrap, followed by analysis of all product ions 
from high-energy collisional dissociation (HCD)25.  With AIF, 48 proteins were detected in a HeLa 
cell lysate; thus the dynamic range is much lower than other DIA methods.   
Another commercially available DIA technique is AB Sciex’s SWATH acquisition on triple TOF 
mass spectrometers.  SWATH is also applicable to other platforms such as the Orbitrap and was 
first designed by the Aebersold lab.  SWATH fragments all ions in the 400-1200 m/z range by 
repeatedly acquiring 32, 25 Da wide windows during a single LC injection with a 1 Da overlap26.  
Thus, SWATH is similar to PAcIFIC, but has larger isolation windows.  Unlike PAcIFIC, the data 
analysis portion involves a targeted data extraction strategy, in which product ions are 
compared to a spectral library containing information on product ion abundance and 
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chromatographic retention times26.  Compared with other DIA strategies, SWATH-MS has a 
relatively high duty cycle and high dynamic range, though the former attribute is not as high as 
for MSE and the latter is not as high as in PAcIFIC26.  The data analysis strategy has recently been 
improved for SWATH-MS through automation27.  SWATH is a modification of a previous method 
originating in the Yates lab.  This method fragments ions in windows of 10 or 20 Da with no 
overlapping m/z values28.  The Yates method utilizes MudPIT and metabolic labeling for 
increased chromatographic resolution and quantification, respectively.  Although the Yates 
method is very similar to SWATH, it suffers from a slightly lower throughput and a lower 
dynamic range due to the difference in instrumentation and the comparative lack of data 
mining.  Additionally, the Yates method identified a much lower number of proteins and 
peptides than similar methods with wide isolation windows although all methods analyzed 
whole cell lysates. 
One of DIA’s main advantages is also a disadvantage: the rich and complex data sets it 
produces renders data analysis challenging and time consuming.  The OpenSWATH program 
adds a huge advantage, as it is applicable for multiple DIA data sets across different vendors 
and greatly simplifies data analysis.  XDIA is an alternative computational strategy, which 
combines two MS/MS techniques, electron transfer dissociation and collision-induced 
dissociation (CID), to deconvolute complex spectra29.  DeMux is another program designed to 
deconvolute complex data sets resulting from DIA, however, it is only applicable to data from 
ion trap mass spectrometers30.  Upon designing DeMux, the authors found that data 
independent MS/MS provides more reproducible results, a necessary aspect for proteomics 
experiments.  DIA-Umpire is a new program that enables untargeted peptide identification 
from DIA-derived data, using spectral libraries31.  MS/MS data are matched against these 
spectral libraries.  Quantitation can be performed with either precursor ions or fragment ions 
intensities.  Additionally, DIA-Umpire is open-source and is applicable to numerous DIA 
strategies. 
 
Method Description Max # proteins/peptides 
(original paper) 
PAcIFIC Fragments all peptides in 2.5 Da 2320 proteins, 13,049 peptides 
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windows, overlap of 1.5 m/z in 
windows 
MSE Alternates low collision energy scan 
(MS) and high collision energy (MS/MS) 
scan 
N/A metabolites - not whole cell 
lysate 
All Ion Fragmentation MS scan in orbitrap followed by MS/MS 
scan in HCD cell 
45 proteins, 348 peptides  
SWATH-MS Fragments all peptides in 25 Da 
windows, 1 m/z overlap in windows 
original paper cites 4 log 
dynamic range, SWATH website 
cites over 3000 proteins32 
DIA- Yates lab Fragments all peptides in 10 or 20 Da 
windows, no overlap of m/z in windows 
599 proteins, 1933 peptides 
Table 5.1. A summary of various DIA approaches. 
Data independent approaches to complex biological samples increase the prospects for 
detection of relevant peptides or proteins of low abundance.  We are particularly interested in 
applying DIA techniques to cell extracts from natural product biosynthetic organisms.  Such 
organisms express large polyketide synthases (PKSs) and/or non-ribosomal peptide synthetases 
(NRPSs), responsible for synthesizing bioactive natural products.  These proteins include acyl 
carrier protein (ACP) and peptidyl carrier protein (PCP) domains, containing a 
phosphopantetheine (Ppant) post-translational modification (PTM).  Via this PTM, natural 
product intermediates are covalently tethered to the biosynthetic protein modules.  Without 
this PTM, the proteins are inactive, or in apo states, whereas, with Ppant attached, the proteins 
are considered active, or in holo states33,34.  Because these large enzymes can easily be 
megadaltons in combined size,33,34 it is highly challenging to detect active site peptides in a 
bottom-up approach.  In addition, many natural product producers have unsequenced 
genomes and/or have symbiont origin, presenting additional challenges.  Although an 
untargeted conventional DDA approach is possible, for example, our research group 
demonstrated detection of tryptic peptides from the ET-743 (a molecule approved as an anti-
cancer drug in Europe) symbiont biosynthetic pathway in a metaproteomic sample, this method 
is akin to pulling a needle from a haystack35.  Therefore, a targeted approach is desired, 
particularly for identifying and interrogating active site peptides.  One example of a targeted 
approach to discovering novel natural products and their associated biosynthetic pathways is 
“proteomic investigation of secondary metabolism” (PrISM)36, based on the gas-phase lability of 
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the Ppant modification37.  This DDA workflow, which can be combined with digestion of only 
high molecular weight gel bands for additional specificity, selectively identifies ACP/PCP active 
site peptides, based on two characteristic PPant ejection product ions; m/z 261.1267 and 
359.1036, resulting from bond cleavage on either side of the Ppant phosphate group.  However, 
this approach only searches for ‘holo’ active site peptides and will miss any Ppantylated peptide 
with an attached substrate.  Also, although a DIA implementation has been proposed38, PrISM 
typically uses DDA and thus comes with all of the associated disadvantages.  Another example 
of a targeted approach for biosynthetic pathway discover is orthogonal active site identification 
system (OASIS), which utilizes chemical probes to target either thioesterases, the protein 
domains found in the terminal PKS/NRPS module, or an ACP/PCP39.  Although OASIS is a 
targeted approach, it has not yet been tested for complex samples and has only been 
implemented on low resolution mass spectrometers.  Additionally, OASIS involves DDA and 
conventional protein databases, which bias the data towards genomes of sequenced 
organisms.  A true unbiased targeted approach in this area is lacking. 
Inspiration for a method to target unsequenced genomes for discovery of novel 
biosynthetic pathways and natural products originates from a selective gas-phase dissociation 
approach for phosphopeptides via infrared multiphoton dissociation (IRMPD)40,41.  The CO2 
laser most frequently used for IRMPD emits photons at a wavelength of 10.6 µm, at which 
phosphate groups strongly absorb42.  Thus, phosphorylated peptides dissociate readily upon IR 
irradiation while unphosphorylated peptides do not40,41.  Research has shown that tyrosine 
phosphorylation is more stable than serine or threonine phosphorylation upon CID43, however, 
with IRMPD, tyrosine phosphopeptides dissociate faster than serine phosphopeptides44.  The 
Brodbelt lab successfully coupled LC to IRMPD-MS in a quadrupole ion trap mass spectrometer 
to separate several mixtures containing unphosphorylated and phosphorylated peptides40.  
Unmodified peptides fluctuate in intensity between 6% and 29% of their original abundances, 
whereas phosphorylated peptides dissociate between 96% and 100%.  This approach was also 
utilized by the same lab for design of chromogenic cross-linkers, containing an ethyl phosphate 
group in the middle of the cross-linker for protein structural analysis45.  Because the Ppant 
modification also contains a secondary phosphate, we hypothesized that IRMPD could be used 
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in a data independent manner for targeted natural product biosynthetic pathway discovery.  
Here, this universal approach, which operates well in both positive and negative ion mode, is 
presented for selective detection of phosphopantetheinylated peptides, regardless of their 
covalent state, i.e., lacking or carrying substrate or product.   
 
5.2 Experimental 
 Proof-of-principle experiments were conducted with a mixture of unphosphorylated 
peptides (bradykinin, angiotensin I, and occasionally substance P) and phosphorylated peptides 
DAM 1 (SFVLNPTNIGM-pS-KSSQGHVTK), NPF (KRS-pY-EEHIP), and the tyrosine phosphorylated 
peptide (H-TSTEPQ-pY-QPGENL-NH2).  Peptides were purchased from Sigma-Aldrich, except for 
the tyrosine phosphorylated peptide which was purchased from Millipore.  Data independent 
LC/FT-ICR MS/MS was performed with a hydrophilically endcapped C18 column (Phenomenex 
Synergi Hydro 80 Å 4 µm 1 x 150 mm).  A non-linear gradient of 2-98% acetonitrile with 0.1% 
formic acid over ninety minutes was generated with an Agilent 1100 HPLC coupled to a 7 Tesla 
Apex or SolariX Q FT-ICR mass spectrometer (Bruker Daltonics).  The gradient was as follows 
(with isocratic elution between 40 and 50 min): 0 (98,2), 20 (70,30), 40 (50,50), 50 (50,50), 55 
(30,70), 70 (2,98).  Values are provided as time (%A, %B) over a total run time of 95 min.  Flow 
was at 50 µl/min and was diverted for the first 5 min of the run.  HPLC solvent A was 0.1% 
formic acid (ThermoFisher Scientific) in HPLC-grade water (ThermoFisher Scientific) and solvent 
B was 0.1% formic acid in acetonitrile (ThermoFisher Scientific).  IRMPD was performed with a 
25 W CO2 laser (Synrad) between 40% and 60% power with a 100 to 150 millisecond irradiation 
time.   
The CurM ACP from the Curacin biosynthetic pathway46 is 119 amino acids long, 
corresponding to 13,379 Da.  The protein’s concentration was 50 µM and it was kept in a buffer 
containing 10 µM of Streptomyces verticillus ATCC15003 (SVP), 10 mM of MgCl2 and 100 mM of 
Tris at pH 7.5.  The protein was expressed and purified by a member of the Sherman Lab at the 
University of Michigan and fractions were collected between 50 and 55 minutes for the apo and 
holo protein, respectively.  Apo and holo ACPs were digested with sequencing grade trypsin at 
37 degrees Celsius for 16 hours.  The LC gradient was identical to the gradient for the proof-of-
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principle experiment.  IRMPD was performed with a 25 W CO2 laser at 50% power with a 100 
ms irradiation time.   
PikAIII from the pikromycin biosynthetic pathway47,48 is 1,562 amino acids long, 
corresponding to 163,593 Da.  The dimeric Pik module was expressed, purified and digested by 
a member of the Smith lab at the University of Michigan.  PikAIII was digested with sequencing 
grade trypsin for 15 minutes at a 4:1 protein:trypsin ratio and quenched with formic acid.  The 
final protein concentration was 1 μM.  The LC gradient was identical to the gradient for the 
proof-of-principle phoshopeptide experiment.  IRMPD was performed with a 25 W CO2 laser at 
40% power with a 100 millisecond irradiation time.  External calibration for all experiments 
utilized HP-mix (Agilent) or 0.1 mg/mL sodium trifluoroacetate clusters (Sigma-Aldrich). The 
intelligent pulse sequence organizer (IPSO) was re-programmed to allow the d12 command to 
trigger IRMPD rather than electron capture dissociation, thus firing the laser in every other 
LC/MS/MS scan on the SolariX instrument.  Quadrupole isolation was turned off in all cases to 
allow DIA.   
 
5.3 Results and Discussion 
5.3.1 Implementation of DIA LC/IRMPD: Proof-of-Principle and Optimization 
 Initially, all experiments were conducted on the older Apex-Q FT-ICR mass 
spectrometer.  Apex does not have the IPSO program; therefore, peptides were compared from 
separate LC/MS runs, i.e, one run with the laser off and one with the laser on.  On the Apex 
instrument, the laser was tuned for optimum power and irradiation time through direct 
injection of the peptide mixture, as shown in Table 5.2. 
Laser Power 40% 40% 40% 40% 40% 40% 40% 50% 60% 60% 
Irradiation Time 
( s) 
0 0.05 0.10 0.15 0.20 0.25 0.30 0.15 0.15 0.10 
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Bradykinin (A) 100% 94% 95% 101% 82% 79% 49% 92% 90% 102% 
Angiotensin I (B) 100% 89% 91% 90% 74% 71% 36% 79% 82% 88% 
Substance P (C) 100% 90% 92% 103% 61% 59% 30% 77% 63% 94% 
DAM1 (M) 100% 95% 82% 68% 27% 27% 17% 37% 29% 79% 
pY peptide (N) 100% 82% 36% 26% 15% 14% 11% 24% 21% 34% 
Table 5.2. Different laser powers and irradiation times were tested to find the optimal 
condition for selective IRMPD.  Shown in the table are the relative abundance of the selected 
ions (A [A + 2H]2+, B [B + 2H]2+, C [C + 2H]2+, M [M + 3H]3+, and N [N + K  + H]2+) following IR 
irradiation.  A laser power of 60% and an irradiation time of 0.15 s were chosen as the 
abundance of phosphorylated species (M, N) were significantly reduced upon IR irradiation 
whereas the unphosphorylated species (A, B, C) were not.  Data collected by a summer 
undergraduate student under my supervision, Yilun Li. 
 Following optimization of the laser power and irradiation time, the peptide mix was subjected 
to LC/FT-ICR MS with and without laser irradation.  This proof-of-principle experiment was 
successful in that all five peptides were detected.  Peak areas from extracted ion 
chromatograms (EICs) with and without IR irradiation remained within 43 percent of each other 
for the unphosphorylated peptides.  The tyrosine phosphopeptide’s EIC peak area decreased by 
about 96 percent, whereas the DAM1 EIC peak area completely disappeared upon IR 
irradiation, thus demonstrating selectivity of IRMPD for phosphopeptide dissociation (Figure 
5.1).   
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Figure 5.1. Extracted ion chromatograms (EICs) of the monoisotopic peak of the 
unphosphorylated and phosphorylated peptides without (blue) and with (red) IR irradiation 
from separate LC/MS runs on an Apex-Q FT-ICR mass spectrometer.  Unmodified peptides’ peak 
areas decreases by less than fifty percent upon irradiation, whereas phosphorylated peptides 
decreased greater than 95 percent. 
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An added advantage of this DIA method is that it is insensitive to ion polarity (Figure 
5.2).  The by far most common way of analyzing peptides in a mass spectrometer is in positive 
ion mode, in which the ion source forms positively charged analytes.  However, acidic 
molecules, such as phosphorylated peptides and proteins, can be difficult to ionize in positive 
ion mode49.  Analyzing acidic analytes in negative ion mode can increase the sensitivity and 
limit of detection50,51.  Therefore, it is important to develop and operate complementary 
fragmentation techniques and data-independent strategies in both polarities.  Operating this 
data independent method in both positive and negative ion modes may increase the number of 
identified Ppant-containing peptides as complementary ionization is known to occur between 
the two modes.   
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Figure 5.2. The identities of peptides A, B, C, M, and N are listed in Table 5.2.  The unmodified 
peptides A, B, and C do not dissociate efficiently upon IR irradiation in neither positive (top), 
nor negative (bottom) ion mode.  Phosphorylated peptides nearly completely dissociate in both 
ionization modes.  The b10 - H2O fragment ion colored in purple is from the M peptide, also 
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labeled in purple.  The N peptide loses phosphoric acid upon irradiation; both precursor and 
fragment ions are color coded in green. 
 
Although the older Apex instrument yielded satisfactory data, the LC peaks were undersampled 
and thus have triangular shapes, as seen in Figure 5.1.  The observed slight shift in retention 
time with and without IR irradiation is due to the separate LC/MS runs.  Furthermore, between 
seemingly identical LC/MS runs, there may be differences in ionization efficiency and ion 
transport; therefore, it would be ideal to implement our DIA approach in a single LC/MS run 
with the IR laser firing every other scan.  This improvement would allow for twice the number 
of runs during a set duration.  Therefore, the IR laser was moved to the newer SolariX mass 
spectrometer and a modified pulse program was written to allow for LC/MS with the laser firing 
every other scan.  The SolariX instrument is more sensitive than the Apex instrument and writes 
data to the hard drive faster, thus allowing for more data acquisition points in a given time 
period.  Moreover, SolariX has a more advanced pulse programming capability (IPSO) than 
Apex.  The default MS/MS activation methods for LC/MS/MS on SolariX are CID and electron 
capture dissociation (ECD) with the d12 parameter controlling the electron irradiation time.  
The IPSO was manipulated to instead trigger the infrared laser during d12.  A 27 pin connector 
for external triggering was connected to the laser.  This SolariX implementation resulted in 
more reliable retention times and improved peak shapes as well as a more accurate comparison 
of the peak shapes prior to and after irradiation, as compared with the Apex implementation.  
For quantitation purposes, EICs were created for all observed isotopic peaks above a signal to 
noise ratio of three.  On SolariX, the laser power and irradiation time were reduced to 40% and 
100 ms, respectively, for optimal conditions.  When more than on peptide charge state was 
observed, peaks areas were normalized to charge and summed.  The NPF peptide dissociated 
by 93% and the pY peptide dissociated by 99%.  The unmodified peptides, bradykinin and 
angiotensin I dissociated by 4% and increased by 12%, respectively, as shown in Figure 5.3.   
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Figure 5.3. DIA LC/FT-ICR MS of a mixture of four peptides, half unmodified, half 
phosphorylated, on a newer SolariX Q-FT-ICR mass spectrometer with the laser firing every 
other scan.  This experiment resulted in smoother peak shapes than the data in Fig. 5.1 with 
retention times completely overlapping due to the MS and IRMPD data being collected in the 
same run.  Overall, similar results ensued, with unmodified peptides partially dissociating, 
whereas phosphorylated peptides dissociated nearly to completion. 
5.3.2 DIA LC/IRMPD of an acyl carrier protein 
After the proof-of principle experiments were successful, a single ACP was tryptically 
digested and subjected to data-independent LC/IRMPD to explore whether the Ppant-modified 
active site peptide would show analogous behavior to the phosphopeptides above and to the 
previously published phosphate-containing cross-linker45.  The CurM ACP from the curacin A 
hybrid PKS/NRPS biosynthetic pathway was selected for this experiment, which was carried out 
on the older Apex instrument, due to availability and laser location at the time.  Ten tryptic 
peptides, including one that contained Ppant, were detected in LC/MS as well as in LC/IRMPD 
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analysis.  Upon IR irradiation, the Ppant-containing peptide decreased in peak area by 88%, as 
determined from the EIC (Figure 5.4).  The EIC peak area difference without and with IR 
irradiation for unmodified peptides ranged from 3 to 29 percent.  This experiment 
demonstrated the selectivity of the DIA IRMPD method for a more complex sample and 
confirmed our hypothesis that the Ppant modification would show selective dissociation. 
 
Figure 5.4.  LC/FT-ICR MS without (blue) and with (red) IR irradiation.  The top spectrum 
demonstrates the effectiveness of IRMPD for a phosphopantetheinylated peptide with a 
decrease in EIC peak area by 88%.  An example unmodified peptide, LQAAPITER, only 
dissociated by 3%.  In this tryptic digest, unmodified peptides dissociated 29% or less.   
 
5.3.3 DIA LC/IRMPD of a polyketide synthase module 
 The selectivity of the established data-independent LC/IRMPD method was further 
validated for the fifth module from the pikromycin biosynthetic pathway, PikAIII.  This module 
was selected due to familiarity with the pikromycin biosynthetic pathway.  PikAIII consists of 
four domains, a ketosynthase, an acyl transferase, an ACP, and a ketoreductase.  The 
application to an entire PKS module increases sample complexity from a single ACP (MW 
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13,379) to greater than 150 kDa.  All PikAIII LC/IRMPD replicates were carried out on the SolariX 
mass spectrometer, ensuring higher quality chromatography data and higher sensitivity.  For 
comparison, active site peptides from the ketosynthase and acyl transferase domains were 
selected, as well as other abundant unmodified peptides.   
 
Figure 5.5.  Extracted ion chromatograms of the active site holo ACP peptide without and with 
IR irradiation (top).  FT-ICR mass spectra (bottom) verify the loss in signal abundance upon IR 
irradiation.  The holo ACP active site peptide (containing Ppant) dissociates by 73%.  
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Figure 5.6. EICs of selected unmodified peptides from a PikAIII tryptic digest without (blue) and 
with (red) IR irradiation.  Peak areas decrease less than that of holo ACP (Fig. 5.5).  When 
multiple charge states were present, peaks were normalized to charge and summed.  The acyl 
transferase and ketosynthase active site peptides are shown as well as a PikAIII non-active site 
peptide that was abundant in each replicate. 
 The IR laser was tuned and optimized prior to each LC/IRMPD run, data were collected 
with 55% power and 200 ms irradiation time, with 50% power and 150 ms irradiation time, and 
ultimately with 40% power and 100 ms irradiation, chosen as the optimal condition for PikAIII.  
Overall, the experiment was successful in that the holo ACP dissociated more readily than 
unmodified peptides, 73% (Figure 5.5).  For relative quantitation, EICs for all isotopic peaks 
above a signal to noise ratio of three were created.  Three selected unmodified peptides 
dissociated by 49%, 55%, and 40%, respectively (Figure 5.6).  Thus, for the PikAIII digest, there 
was a smaller difference in dissociation percentage between unmodified and Ppantylated 
peptides than the previous experiments.  When the laser power and irradiation time were 
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increased, the PPantylated peptide dissociated up to 93%, however, the unmodified peptides 
dissociated at a higher percent as well, particularly the acyl transferase active site peptide.  
Experiments to further optimize the laser power and/or irradiation time may improve 
selectivity between unmodified and Ppantylated peptides and should be carried out in the 
future. 
5.4 Conclusions 
 A novel data independent LC/IRMPD approach has been developed to selectively detect 
phosphopantetheinylated peptides from PKS and NRPS biosynthetic pathways.  Targeted and 
unbiased proteomic approaches are lacking in the natural product biosynthesis field and this 
method fills this gap.  IRMPD selectively detects and dissociates phosphopantetheinylated 
peptides, allowing for eventual discovery of novel natural product biosynthetic pathways.  This 
method was optimized and established in proof-of-principle experiments with a mixture of 
unmodified and phosphorylated peptides.  Subsequently, the complexity of the sample was 
increased to a single ACP domain and further to a single module from a PKS biosynthetic 
pathway.  Future work for further development and improvement of this method includes 
additional optimization for the PKS module and further increase in complexity to the 
overexpressed pikromycin biosynthetic pathway in an E. coli lysate and eventually lysates of 
Streptomyces venezuelae, the native pikromycin producer.  This method will eventually be 
applied to organisms with unsequenced genomes, such as Karenia brevis, a marine 
dinoflagellate responsible for producing multiple natural products, including a potential 
respiratory therapeutic and a toxin responsible for the Florida red tides. 
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Chapter 6 
Conclusions and Future Directions 
 
 
6.1 Dissertation Summary  
Although each chapter in this dissertation tells a distinct story, each involves Fourier 
transform ion cyclotron resonance (FT-ICR) mass spectrometric quantitation of dynamic 
peptides or proteins that change abundance or modifications readily.  Chapter 2 explored the 
phosphorylation kinetics of Sic1, a protein in budding yeast.  Phosphorylation of six of the nine 
sites triggers a switch-like behavior, resulting in degradation of the protein, which regulates the 
transition from the G1 to the S phase of the cell cycle1,2.  A novel bottom up quantitative 
method was developed to determine the kinetics of each phosphorylation site.  Internal 
standard peptides with Val to Leu or Leu to Val substitutions were tested for similar ionization 
efficiencies and served as internal standard peptides for the quantitative method.  If a Val or 
Leu was not present in the Sic1 peptide of interest, a proline was labeled with 13C and 15N.  
Additionally, all spectra were collected in negative ion mode and the first three isotopes were 
quantified to ensure accuracy, particularly for low signal to noise ratio peptides.  To establish 
the technique, a mutant protein was quantified, Sic1 2p, in which every phosphorylation site 
except T45 and S76 were mutated to an alanine.  The two phosphorylation sites had different 
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phosphorylation rates, with S76 phosphorylating faster than T45.  Phosphorylation rates for 
each known Sic1 phosphorylation site in the wildtype protein were determined with bottom-up 
FT-ICR mass spectrometry (MS).  For the 33-50 peptide with two proline-directed 
phosphorylation sites, evidence for a third phosphorylation event was found, although the site 
of additional phosphorylation proved difficult to determine with tandem mass spectrometry 
(MS/MS) due to its relatively low abundance.  Evidence for a total of ten phosphorylation 
events was also seen in previous top down experiments in our laboratory3.  Each of the nine 
known sites on the wildtype protein has a different phosphorylation rate, with T45, S76, T5, and 
T33 phosphorylating faster than T2, S69, S80, T173 and S191.  These findings agree with 
previously published data stating that the four aforementioned sites contribute more 
significantly to Sic1 degradation1.  Future work for this project includes comparing the kinetic 
data with mathematical models and repeating the experiments in vivo. 
Chapter 3 confirmed, identified, and quantified substrate- and product-bound active site 
peptides in the fifth module of the pikromycin biosynthetic pathway, the polyketide synthase 
(PKS) PikAIII.  Changes in the small molecule occupancy of the different active sites in this PKS 
caused dramatic PKS structural changes, shown with cryo-electron microscopy (cryo-EM).  The 
combination of cryo-EM and ultra-high resolution mass spectrometry provided greater insight 
into how these multienzyme complexes synthesize bioactive natural products.  Ultra-high 
resolution mass spectrometry was necessary for these experiments, particularly to detect a 
mixture of one active site peptide with two different products bound, differing by only two 
hydrogens, i.e. 2 Da.  Relative quantitation was performed by adding the peak areas of all 
detectable isotopes with a signal to noise ratio greater than three for all active site peptides.  
Additionally, the sample preparation and liquid chromatography (LC) steps were optimized by 
eliminating the reduction and alkylation of cysteine residues, choosing an LC column more 
appropriate for peptides, and gradient optimization, allowing for the detection of the 
ketosynthase active site peptide with bound substrate.   
Chapter 4 investigated the effect of two enoyl reductase (ER) domains on a natural product 
intermediate in two pathways from the same organism, Moorea producens.  The jamaicamide 
(Jam) pathway produces Jamaicamide A, a small molecule toxic to fish with sodium channel 
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blocking properties, whereas the curacin (Cur) pathway produces Curacin A, an anti-cancer 
agent4.  The JamJ ER reduces a vinyl chloride, an ER’s typical function, whereas the CurF ER 
produces a cyclopropane. Collision-induced dissociation (CID) was applied to the intact acyl 
carrier proteins (ACPs) excised from the JamJ and CurF PKSs to identify natural product 
intermediates generated by the JamJ and CurF ERs.  High resolution ( 70,000) was necessary to 
detect and identify natural product intermediates: the action of JamJ ER results in a mass 
difference of 2 Da for the intact protein.  High resolution also confirms the MS/MS ejected 
intermediate product: isotopic fine structure is observed due to chlorine in the natural product 
intermediate.  Point mutations near the ER active site were carried out to determine which 
amino acid acts as a proton donor for performing the ER’s function.  Both the JamJ and CurF ER 
mutants show a concentration dependence: 1 or 10 nM of the ER partially reduced a vinyl 
chloride intermediate or partially formed a cyclopropane, whereas 100 nM or greater 
completely reduced the vinyl chloride and mostly (>80%) formed the cyclopropane in the 
presence of NADPH.  JamJ D273 and CurF Y58, Y103, and R253 appear to play significant roles in 
their respective active sites, although no single site is completely responsible for catalytic 
activity, confirming the hypothesis that a water-mediated pathway may be the proton donor 
necessary for catalytic activity5,6.  Natural product intermediates were relatively quantified to 
determine the effects of ER mutations.  Additionally, the JamJ R251K mutant was further 
altered to incorporate a structural loop from Cur, resulting in a novel cyclopropanase.  The 
cyclopropanase activity was confirmed and quantified with mass spectrometry.   
Chapter 5 strove to develop a novel data-independent acquisition method for discovery of 
novel PKS and non-ribosomal peptide synthetase (NRPS) pathways in unsequenced organisms.  
This approach is also novel in that it is a targeted approach toward the phosphopantetheine 
(Ppant) moiety, which is responsible for tethering and transferring natural product 
intermediates.  Infrared multiphoton dissociation (IRMPD) at 10.6 µM selectively dissociates 
peptides with both primary and secondary phosphates7,8.  Ppant, a post-translational 
modification of ACPs and peptidyl carrier proteins (PCPs) in NRPSs has a secondary phosphate, 
acting as a chromophore for the IR photons9.  As proof-of-principle, a mixture of phospho- and 
non-phosphopeptides was subjected to LC/FT-ICR MS without and with IR irradiation.  
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Phosphopeptides decreased in peak area by 80-99 percent, whereas unmodified peptides 
decreased in peak area by less than twenty nine percent.  Ten peptides, including one 
containing Ppant, were found in LC/FT-ICR MS analysis of tryptically digested CurM ACP from 
the curacin A biosynthetic pathway.  With IRMPD, all unmodified peptides decreased in peak 
area by 30 percent or less, including some peptides that increased in peak area.  With IRMPD, 
the Ppant-containing peptide decreased in peak area by 88 percent.  The complexity of the 
mixture was increased to an entire module of a polyketide synthase, module five from the 
pikromycin biosynthetic pathway.  Unmodified peptide peak areas decreased by 55 percent or 
less, whereas the phosphopantetheinylated peptide’s peak area decreased by 73 percent.  We 
are currently exploring the applicability of this method, which can be conducted in either 
positive or negative ion mode, for more complex NRPS/PKS mixtures.   
 
6.2 Prospects for Future Work 
6.2.1 Polyketide synthase natural product discovery 
 Bolstered by the success of the combination of cryo-EM and LC/FT-ICR mass 
spectrometry described in Chapter 3, there are already future projects in the works for 
additional PKS and NRPS systems.  For example, PikAIV, the module following PikAIII, is thought 
to be much less specific in regard to substrate size and structure than PikAIII10,11.  Determining 
the structural differences that could point to the specificity differences in the two modules is an 
important question.  Although cryo-EM data has not yet been collected, some preliminary mass 
spectrometry data for trapped catalytic intermediates in PikAIV have been collected.  PikAIV 
condenses the β-hydroxyhexaketide from PikAIII with methyl-malonyl (MM) to form a 
heptaketide.  We were able to detect PikAIV ACP-bound heptaketide at high yield in a construct 
for which the terminal thioesterase (which off-loads this product) was knocked out.  Additional 
active site peptides with bound substrates were also identified and quantified with FT-ICR mass 
spectrometry, as summarized in Figure 6.1.  Chapter 3 made several protocol changes from a 
previous lab member’s procedures, including reducing the trypsin digestion time to fifteen 
minutes to avoid hydrolyzation.  A 15 minute digestion produced acceptable results.  However, 
it would be advantageous to further reduce the digestion time to increase the chance of 
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trapping intermediates, such as the penta- and hexaketide on the ketosynthases.  Digestion 
times around 1 minute have been reported when coupled with ultrasonication and as low as 50 
seconds for trypsin immobilized on a hybrid silica monolith12,13. 
 
Figure 6.1. Quantitative LC/FT-ICR MS data and depiction of the formation and trapping of 
PikAIV catalytic intermediates.  The generated heptaketide had an unexpectedly high yield.  
PikAIV cartoons generated by Meredith Skiba. 
 Bryostatin-1, a polyketide natural product (see biosynthetic scheme in Figure 6.2), is a 
highly potent inhibitor of protein kinase C and has been investigated as an agent against cancer, 
HIV, and Alzheimer’s14,15.  Additionally, bryostatin-1 could bring back memory loss subsequent 
to a postischemic stroke16.  Although this molecule shows great promise, the bryostatins are 
produced from the bacterium, Candidatus Endobugula sertula, which is unculturable17.  As a 
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result, it is a costly product, about $14 million/gram.  For total synthesis, the lowest number of 
steps reported to date is thirty.   
 
Figure 6.2. The bryostatin biosynthetic pathway.  Only one product, bryostatin-1, is shown, 
though there are several other natural products that are produced by this pathway.  Figure 
from Buchholz et al18. 
The bryostatins are another example of the need for chemoenzymatic synthesis.  The enzymatic 
selectivity of BryR, a portion of the bryostatin biosynthetic pathway, has been investigated by 
determining binding affinities between BryR and ACPs from other biosynthetic pathways18.  The 
great therapeutic potential of the bryostatin family may be further developed by feeding 
unnatural substrates into the bryostatin pathway to form novel natural products, or to create 
more efficient natural products.  FT-ICR mass spectrometry would be a valuable tool for 
confirming and quantifying active site occupancy and kinetics of each module.   
6.2.2 Determination of PikAIII dynamics via hydrogen/deuterium exchange mass 
spectrometry 
137 
 
One of the most surprising discoveries in the PikAIII structural analysis (Chapter 3) was 
the end-to-end flip of the ketoreductase (KR) domain upon addition of thiophenol-pentaketide 
(Figure 6.3)19.  Although the reason for this end-to-end flip was speculated upon; the flip brings 
the KR active site closer to the ACP active site, the mechanism of the flip is unknown.   
 
Figure 6.3.  PikAIII cryo-EM structures fitted with a KR crystal structure from the 6-
deoxyerythronolide B synthase (DEBS) natural product biosynthetic pathway.  An end-to-end 
flip occurs for the KR domain upon addition of the pentaketide substrate to PikAIII.  Figure 
generated by Somnath Dutta. 
The dynamics of the end-to-end flip can be interrogated with hydrogen deuterium exchange 
(HDX) mass spectrometry.  Due to the large size of PikAIII, 150 kDa for the monomer, a bottom-
up approach is the most appropriate for such experiments, with pepsin as the enzyme of 
choice, as it is active at pH 2.5, preventing deuterium back exchange.  The Håkansson lab has 
previously worked in this area and is now returning to this field.  Preliminary experiments have 
been carried out to optimize HDX conditions, such as ratio of protein to pepsin, pepsin 
digestion period, and buffer conditions for protein and pepsin.  Thus far, these conditions have 
been optimized for a small protein, myoglobin (Figure 6.4).  Future experiments will include 
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HDX mass spectrometry on larger proteins, optimizing the conditions for each and finally 
performing HDX mass spectrometry on PikAIII incubated with the pentaketide.  HDX can help 
determine the mechanism of the conformational changes the KR undergoes for the end-to-end 
flip, as solvent exposed amino acids are revealed, leading to more structural insight into this 
natural product biosynthetic pathway.  We have focused on a bottom-up approach, which can 
suffer from lower sequence coverage than its counterparts, top-down and middle-down 
analysis.  However, top-down analysis of a 150 kDa protein is likely beyond the range of a 7T FT-
ICR mass spectrometer.  Therefore, development of a novel middle-down technique may 
increase the KR sequence coverage.  Pepsin is still the ideal enzyme for HDX; therefore, other 
factors must be explored to increase proteolytic peptide size.  Reducing the digestion time, 
increasing the protein to pepsin ratio, or decreasing the digestion temperature may yield larger 
peptides and each of these factors should be explored systematically to optimize the middle-
down approach for highest sequence coverage. 
 
Figure 6.4. Example graph of the mass increase of two peptic peptides from myoglobin upon 
D2O exposure.  The green trace represents a peptide more exposed to solvent than the maroon 
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trace, and thereby showing a larger mass shift.  Data collected with Emma Wang.  Figure 
generated by Emma Wang. 
6.2.3 Data independent LC/IRMPD to identify natural product biosynthetic enzymes in a red 
tide toxin-producing dinoflagellate 
Dinoflagellates such as Karenia brevis (K. brevis) produce secondary metabolites that are 
large and complex, some toxic, whereas others are potential medicines20.  The K. brevis genome 
is rather inaccessible due to its large size, 50-100 times the size of the human genome21.  
Organisms such as these are ideal targets for a data independent LC/MS approach.  A 
collaboration with Dr. David Sherman’s lab has been set up to specifically study natural 
products from this organism, including brevenal, an anti-toxin, that has the potential to treat 
lung diseases, and ladder polyethers, brevetoxins, which are responsible for the dangerous 
Florida red tides (see structures in Figure 6.5)22,23.   
 
Figure 6.5. Brevetoxins are thought to cause the Florida red tides and have also been linked to 
airway complications in humans, whereas the antitoxin brevenal has been shown to provide 
symptomatic relief in diseases such as cystic fibrosis23. 
 
 One approach to discovering the enzymes responsible for generating the brevetoxins and 
brevenal is to synthesize chemical probes designed to locate and isolate either holo-ACPs or the 
thioester bond in the ketosynthase domain.  These chemical probes will also include a primary 
or secondary phosphate group, to allow for the data-independent LC/IRMPD method described 
in Chapter 5.  FT-ICR MS will also be used in model systems to ensure that the probes function 
as desired and are targeting the chosen chemical groups  Once chemical probes have been 
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shown to function well, they can be used to isolate PKSs from K. brevis through affinity 
enrichment, e.g., through incorporation of a biotin functionality.   Data independent LC/IRMPD 
will allow identification of active site biosynthetic peptides, which can be sequenced via an 
arsenal of tandem mass spectrometry techniques.  This sequence information will subsequently 
be used to design PCR primers for amplifying and sequencing the corresponding genes for the 
first time.  This information may also further efforts in sequencing other ladder polyether-
generating organisms.    
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